FHIR Release 3 (STU) R4 Ballot #2 (Mixed Normative/Trial use)

This page is part of the FHIR Specification (v3.0.2: STU 3). (v3.5.0: R4 Ballot #2). The current version which supercedes this version is 5.0.0 . For a full list of available versions, see the Directory of published versions . Page versions: R4 R3

4.3.2.16226 4.4.2.16226 HL7 v3 Value Set ObservationType

Vocabulary Work Group   Maturity Level : N/A External Use Context : Any

This value set (http://hl7.org/fhir/ValueSet/v3-ObservationType) (http://terminology.hl7.org/ValueSet/v3-ObservationType) is defined as part of HL7 v3. Related FHIR content: ObservationType .

Summary

Defining URL: http://hl7.org/fhir/ValueSet/v3-ObservationType http://terminology.hl7.org/ValueSet/v3-ObservationType
Version: 2014-03-26
Name: ObservationType v3.ObservationType
Title: V3 Value SetObservationType
Definition:

Identifies the kinds of observations that can be performed

OID: 2.16.840.1.113883.1.11.16226 (for OID based terminology systems)
Source Resource XML / JSON

This value set is not currently used


This value set includes codes from the following code systems:

 

This expansion generated 19 Apr 2017 Aug 2018


This value set has >1000 codes in it. In order to keep the publication size manageable, only a selection (1000 codes) of the whole set of codes is shown contains 1250 concepts

Expansion based on http://terminology.hl7.org/CodeSystem/v3-ActCode version 2018-08-12

_ObservationType http://hl7.org/fhir/v3/ActCode ObservationType Identifies the kinds of observations that can be performed _ActSpecObsCode http://hl7.org/fhir/v3/ActCode ActSpecObsCode Identifies the type of observation that is made about a specimen that may affect its processing, analysis or further result interpretation _AnnotationType http://hl7.org/fhir/v3/ActCode AnnotationType AnnotationType _GeneticObservationType http://hl7.org/fhir/v3/ActCode GeneticObservationType Description: None provided _IndividualCaseSafetyReportType http://hl7.org/fhir/v3/ActCode Individual Case Safety Report Type A code that is used to indicate the type of case safety report received from sender. The current code example reference is from the International Conference on Harmonisation (ICH) Expert Workgroup guideline on Clinical Safety Data Management: Data Elements for Transmission of Individual Case Safety Reports. The unknown/unavailable option allows the transmission of information from a secondary sender where the initial sender did not specify the type of report. Example concepts include: Spontaneous, Report from study, Other. _LOINCObservationActContextAgeType http://hl7.org/fhir/v3/ActCode LOINCObservationActContextAgeType Definition:The set of LOINC codes for the act of determining the period of time that has elapsed since an entity was born or created. _MedicationObservationType http://hl7.org/fhir/v3/ActCode MedicationObservationType MedicationObservationType _ObservationIssueTriggerCodedObservationType http://hl7.org/fhir/v3/ActCode ObservationIssueTriggerCodedObservationType Distinguishes the kinds of coded observations that could be the trigger for clinical issue detection. These are observations that are not measurable, but instead can be defined with codes. Coded observation types include: Allergy, Intolerance, Medical Condition, Pregnancy status, etc. _CaseTransmissionMode http://hl7.org/fhir/v3/ActCode case transmission mode Code for the mechanism by which disease was acquired by the living subject involved in the public health case. Includes sexually transmitted, airborne, bloodborne, vectorborne, foodborne, zoonotic, nosocomial, mechanical, dermal, congenital, environmental exposure, indeterminate. _ObservationSequenceType http://hl7.org/fhir/v3/ActCode ObservationSequenceType ObservationSequenceType _ObservationSeriesType http://hl7.org/fhir/v3/ActCode ObservationSeriesType ObservationSeriesType _ECGObservationSeriesType http://hl7.org/fhir/v3/ActCode ECGObservationSeriesType ECGObservationSeriesType _PopulationInclusionObservationType http://hl7.org/fhir/v3/ActCode PopulationInclusionObservationType Observation types for specifying criteria used to assert that a subject is included in a particular population. _PreferenceObservationType http://hl7.org/fhir/v3/ActCode _PreferenceObservationType Types of observations that can be made about Preferences. _ActAdministrativeDetectedIssueCode http://hl7.org/fhir/v3/ActCode ActAdministrativeDetectedIssueCode Identifies types of detectyed issues for Act class "ALRT" for the administrative and patient administrative acts domains. _ActAdministrativeAuthorizationDetectedIssueCode http://hl7.org/fhir/v3/ActCode ActAdministrativeAuthorizationDetectedIssueCode ActAdministrativeAuthorizationDetectedIssueCode _ActAdministrativeRuleDetectedIssueCode http://hl7.org/fhir/v3/ActCode ActAdministrativeRuleDetectedIssueCode ActAdministrativeRuleDetectedIssueCode _ActSuppliedItemDetectedIssueCode http://hl7.org/fhir/v3/ActCode ActSuppliedItemDetectedIssueCode Identifies types of detected issues regarding the administration or supply of an item to a patient. _AdministrationDetectedIssueCode http://hl7.org/fhir/v3/ActCode AdministrationDetectedIssueCode Administration of the proposed therapy may be inappropriate or contraindicated as proposed _AppropriatenessDetectedIssueCode http://hl7.org/fhir/v3/ActCode AppropriatenessDetectedIssueCode AppropriatenessDetectedIssueCode _InteractionDetectedIssueCode http://hl7.org/fhir/v3/ActCode InteractionDetectedIssueCode InteractionDetectedIssueCode _TimingDetectedIssueCode http://hl7.org/fhir/v3/ActCode TimingDetectedIssueCode Proposed therapy may be inappropriate or ineffective based on the proposed start or end time. _SupplyDetectedIssueCode http://hl7.org/fhir/v3/ActCode SupplyDetectedIssueCode Supplying the product at this time may be inappropriate or indicate compliance issues with the associated therapy _FDALabelData http://hl7.org/fhir/v3/ActCode FDALabelData FDA label data
Code System Display Definition
ARTBLD http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode ActSpecObsArtBldCode Describes the artificial blood identifier that is associated with the specimen.
DILUTION http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode ActSpecObsDilutionCode An observation that reports the dilution of a sample.
AUTO-HIGH http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Auto-High Dilution The dilution of a sample performed by automated equipment. The value is specified by the equipment
AUTO-LOW http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Auto-Low Dilution The dilution of a sample performed by automated equipment. The value is specified by the equipment
PRE http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Pre-Dilution The dilution of the specimen made prior to being loaded onto analytical equipment
RERUN http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Rerun Dilution The value of the dilution of a sample after it had been analyzed at a prior dilution value
EVNFCTS http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode ActSpecObsEvntfctsCode Domain provides codes that qualify the ActLabObsEnvfctsCode domain. (Environmental Factors)
INTFR http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode ActSpecObsInterferenceCode An observation that relates to factors that may potentially cause interference with the observation
FIBRIN http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Fibrin The Fibrin Index of the specimen. In the case of only differentiating between Absent and Present, recommend using 0 and 1
HEMOLYSIS http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Hemolysis An observation of the hemolysis index of the specimen in g/L
ICTERUS http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Icterus An observation that describes the icterus index of the specimen. It is recommended to use mMol/L of bilirubin
LIPEMIA http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Lipemia An observation used to describe the Lipemia Index of the specimen. It is recommended to use the optical turbidity at 600 nm (in absorbance units).
VOLUME http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode ActSpecObsVolumeCode An observation that reports the volume of a sample.
AVAILABLE http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Available Volume The available quantity of specimen. This is the current quantity minus any planned consumption (e.g., tests that are planned)
CONSUMPTION http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Consumption Volume The quantity of specimen that is used each time the equipment uses this substance
CURRENT http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Current Volume The current quantity of the specimen, i.e., initial quantity minus what has been actually used.
INITIAL http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Initial Volume The initial quantity of the specimen in inventory
_ActPatientAnnotationType http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode ActPatientAnnotationType Description:Provides a categorization for annotations recorded directly against the patient .
ANNDI http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode diagnostic image note Description:A note that is specific to a patient's diagnostic images, either historical, current or planned.
ANNGEN http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode general note Description:A general or uncategorized note.
ANNIMM http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode immunization note A note that is specific to a patient's immunizations, either historical, current or planned.
ANNLAB http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode laboratory note Description:A note that is specific to a patient's laboratory results, either historical, current or planned.
ANNMED http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode medication note Description:A note that is specific to a patient's medications, either historical, current or planned.
GENE http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode gene Description: A DNA segment that contributes to phenotype/function. In the absence of demonstrated function a gene may be characterized by sequence, transcription or homology
_ImmunizationObservationType http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode ImmunizationObservationType Description: Observation codes which describe characteristics of the immunization material.
OBSANTC http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode antigen count Description: Indicates the valid antigen count.
OBSANTV http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode antigen validity Description: Indicates whether an antigen is valid or invalid.
PAT_ADV_EVNT http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode patient adverse event Indicates that the ICSR is describing problems that a patient experienced after receiving a vaccine product.
VAC_PROBLEM http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode vaccine product problem Indicates that the ICSR is describing a problem with the actual vaccine product such as physical defects (cloudy, particulate matter) or inability to confer immunity.
21611-9 http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode age patient qn est Definition:Estimated age.
21612-7 http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode age patient qn reported Definition:Reported age.
29553-5 http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode age patient qn calc Definition:Calculated age.
30525-0 http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode age patient qn definition Definition:General specification of age with no implied method of determination.
30972-4 http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode age at onset of adverse event Definition:Age at onset of associated adverse event; no implied method of determination.
REP_HALF_LIFE http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode representative half-life Description:This observation represents an 'average' or 'expected' half-life typical of the product.
SPLCOATING http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode coating Definition: A characteristic of an oral solid dosage form of a medicinal product, indicating whether it has one or more coatings such as sugar coating, film coating, or enteric coating. Only coatings to the external surface or the dosage form should be considered (for example, coatings to individual pellets or granules inside a capsule or tablet are excluded from consideration). Constraints: The Observation.value must be a Boolean (BL) with true for the presence or false for the absence of one or more coatings on a solid dosage form.
SPLCOLOR http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode color Definition: A characteristic of an oral solid dosage form of a medicinal product, specifying the color or colors that most predominantly define the appearance of the dose form. SPLCOLOR is not an FDA specification for the actual color of solid dosage forms or the names of colors that can appear in labeling. Constraints: The Observation.value must be a single coded value or a list of multiple coded values, specifying one or more distinct colors that approximate of the color(s) of distinct areas of the solid dosage form, such as the different sides of a tablet or one-part capsule, or the different halves of a two-part capsule. Bands on banded capsules, regardless of the color, are not considered when assigning an SPLCOLOR. Imprints on the dosage form, regardless of their color are not considered when assigning an SPLCOLOR. If more than one color exists on a particular side or half, then the most predominant color on that side or half is recorded. If the gelatin capsule shell is colorless and transparent, use the predominant color of the contents that appears through the colorless and transparent capsule shell. Colors can include: Black;Gray;White;Red;Pink;Purple;Green;Yellow;Orange;Brown;Blue;Turquoise.
SPLIMAGE http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode image Description: A characteristic representing a single file reference that contains two or more views of the same dosage form of the product; in most cases this should represent front and back views of the dosage form, but occasionally additional views might be needed in order to capture all of the important physical characteristics of the dosage form. Any imprint and/or symbol should be clearly identifiable, and the viewer should not normally need to rotate the image in order to read it. Images that are submitted with SPL should be included in the same directory as the SPL file.
SPLIMPRINT http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode imprint Definition: A characteristic of an oral solid dosage form of a medicinal product, specifying the alphanumeric text that appears on the solid dosage form, including text that is embossed, debossed, engraved or printed with ink. The presence of other non-textual distinguishing marks or symbols is recorded by SPLSYMBOL. Examples: Included in SPLIMPRINT are alphanumeric text that appears on the bands of banded capsules and logos and other symbols that can be interpreted as letters or numbers. Constraints: The Observation.value must be of type Character String (ST). Excluded from SPLIMPRINT are internal and external cut-outs in the form of alphanumeric text and the letter 'R' with a circle around it (when referring to a registered trademark) and the letters 'TM' (when referring to a 'trade mark'). To record text, begin on either side or part of the dosage form. Start at the top left and progress as one would normally read a book. Enter a semicolon to show separation between words or line divisions.
SPLSCORING http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode scoring Definition: A characteristic of an oral solid dosage form of a medicinal product, specifying the number of equal pieces that the solid dosage form can be divided into using score line(s). Example: One score line creating two equal pieces is given a value of 2, two parallel score lines creating three equal pieces is given a value of 3. Constraints: Whether three parallel score lines create four equal pieces or two intersecting score lines create two equal pieces using one score line and four equal pieces using both score lines, both have the scoring value of 4. Solid dosage forms that are not scored are given a value of 1. Solid dosage forms that can only be divided into unequal pieces are given a null-value with nullFlavor other (OTH).
SPLSHAPE http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode shape Description: A characteristic of an oral solid dosage form of a medicinal product, specifying the two dimensional representation of the solid dose form, in terms of the outside perimeter of a solid dosage form when the dosage form, resting on a flat surface, is viewed from directly above, including slight rounding of corners. SPLSHAPE does not include embossing, scoring, debossing, or internal cut-outs. SPLSHAPE is independent of the orientation of the imprint and logo. Shapes can include: Triangle (3 sided); Square; Round; Semicircle; Pentagon (5 sided); Diamond; Double circle; Bullet; Hexagon (6 sided); Rectangle; Gear; Capsule; Heptagon (7 sided); Trapezoid; Oval; Clover; Octagon (8 sided); Tear; Freeform.
SPLSIZE http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode size Definition: A characteristic of an oral solid dosage form of a medicinal product, specifying the longest single dimension of the solid dosage form as a physical quantity in the dimension of length (e.g., 3 mm). The length is should be specified in millimeters and should be rounded to the nearest whole millimeter. Example: SPLSIZE for a rectangular shaped tablet is the length and SPLSIZE for a round shaped tablet is the diameter.
SPLSYMBOL http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode symbol Definition: A characteristic of an oral solid dosage form of a medicinal product, to describe whether or not the medicinal product has a mark or symbol appearing on it for easy and definite recognition. Score lines, letters, numbers, and internal and external cut-outs are not considered marks or symbols. See SPLSCORING and SPLIMPRINT for these characteristics. Constraints: The Observation.value must be a Boolean (BL) with <u>true</u> indicating the presence and <u>false</u> for the absence of marks or symbols. Example:
AIRTRNS http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode airborne transmission Communication of an agent from a living subject or environmental source to a living subject through indirect contact via oral or nasal inhalation.
ANANTRNS http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode animal to animal transmission Communication of an agent from one animal to another proximate animal.
ANHUMTRNS http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode animal to human transmission Communication of an agent from an animal to a proximate person.
BDYFLDTRNS http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode body fluid contact transmission Communication of an agent from one living subject to another living subject through direct contact with any body fluid.
BLDTRNS http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode blood borne transmission Communication of an agent to a living subject through direct contact with blood or blood products whether the contact with blood is part of a therapeutic procedure or not.
DERMTRNS http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode transdermal transmission Communication of an agent from a living subject or environmental source to a living subject via agent migration through intact skin.
ENVTRNS http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode environmental exposure transmission Communication of an agent from an environmental surface or source to a living subject by direct contact.
FECTRNS http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode fecal-oral transmission Communication of an agent from a living subject or environmental source to a living subject through oral contact with material contaminated by person or animal fecal material.
FOMTRNS http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode fomite transmission Communication of an agent from an non-living material to a living subject through direct contact.
FOODTRNS http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode food-borne transmission Communication of an agent from a food source to a living subject via oral consumption.
HUMHUMTRNS http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode human to human transmission Communication of an agent from a person to a proximate person.
INDTRNS http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode indeterminate disease transmission mode Communication of an agent to a living subject via an undetermined route.
LACTTRNS http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode lactation transmission Communication of an agent from one living subject to another living subject through direct contact with mammalian milk or colostrum.
NOSTRNS http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode nosocomial transmission Communication of an agent from any entity to a living subject while the living subject is in the patient role in a healthcare facility.
PARTRNS http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode parenteral transmission Communication of an agent from a living subject or environmental source to a living subject where the acquisition of the agent is not via the alimentary canal.
PLACTRNS http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode transplacental transmission Communication of an agent from a living subject to the progeny of that living subject via agent migration across the maternal-fetal placental membranes while in utero.
SEXTRNS http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode sexual transmission Communication of an agent from one living subject to another living subject through direct contact with genital or oral tissues as part of a sexual act.
TRNSFTRNS http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode transfusion transmission Communication of an agent from one living subject to another living subject through direct contact with blood or blood products where the contact with blood is part of a therapeutic procedure.
VECTRNS http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode vector-borne transmission Communication of an agent from a living subject acting as a required intermediary in the agent transmission process to a recipient living subject via direct contact.
WATTRNS http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode water-borne transmission Communication of an agent from a contaminated water source to a living subject whether the water is ingested as a food or not. The route of entry of the water may be through any bodily orifice.
_ObservationQualityMeasureAttribute http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode ObservationQualityMeasureAttribute Codes used to define various metadata aspects of a health quality measure.
AGGREGATE http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode aggregate measure observation Indicates that the observation is carrying out an aggregation calculation, contained in the value element.
CMPMSRMTH http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode composite measure method Indicates what method is used in a quality measure to combine the component measure results included in an composite measure.
CMPMSRSCRWGHT http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode component measure scoring weight An attribute of a quality measure describing the weight this component measure score is to carry in determining the overall composite measure final score. The value is real value greater than 0 and less than 1.0. Each component measure score will be multiplied by its CMPMSRSCRWGHT and then summed with the other component measures to determine the final overall composite measure score. The sum across all CMPMSRSCRWGHT values within a single composite measure SHALL be 1.0. The value assigned is scoped to the composite measure referencing this component measure only.
COPY http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode copyright Identifies the organization(s) who own the intellectual property represented by the eMeasure.
CRS http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode clinical recommendation statement Summary of relevant clinical guidelines or other clinical recommendations supporting this eMeasure.
DEF http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode definition Description of individual terms, provided as needed.
DISC http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode disclaimer Disclaimer information for the eMeasure.
FINALDT http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode finalized date/time The timestamp when the eMeasure was last packaged in the Measure Authoring Tool.
GUIDE http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode guidance Used to allow measure developers to provide additional guidance for implementers to understand greater specificity than could be provided in the logic for data criteria.
IDUR http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode improvement notation Information on whether an increase or decrease in score is the preferred result (e.g., a higher score indicates better quality OR a lower score indicates better quality OR quality is within a range).
ITMCNT http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode items counted Describes the items counted by the measure (e.g., patients, encounters, procedures, etc.)
KEY http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode keyword A significant word that aids in discoverability.
MEDT http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode measurement end date The end date of the measurement period.
MSD http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode measurement start date The start date of the measurement period.
MSRADJ http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode risk adjustment The method of adjusting for clinical severity and conditions present at the start of care that can influence patient outcomes for making valid comparisons of outcome measures across providers. Indicates whether an eMeasure is subject to the statistical process for reducing, removing, or clarifying the influences of confounding factors to allow more useful comparisons.
MSRAGG http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode rate aggregation Describes how to combine information calculated based on logic in each of several populations into one summarized result. It can also be used to describe how to risk adjust the data based on supplemental data elements described in the eMeasure. (e.g., pneumonia hospital measures antibiotic selection in the ICU versus non-ICU and then the roll-up of the two). Open Issue: The description does NOT align well with the definition used in the HQMF specfication; correct the MSGAGG definition, and the possible distinction of MSRAGG as a child of AGGREGATE.
MSRIMPROV http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode health quality measure improvement notation Information on whether an increase or decrease in score is the preferred result. This should reflect information on which way is better, an increase or decrease in score.
MSRJUR http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode jurisdiction The list of jurisdiction(s) for which the measure applies.
MSRRPTR http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode reporter type Type of person or organization that is expected to report the issue.
MSRRPTTIME http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode timeframe for reporting The maximum time that may elapse following completion of the measure until the measure report must be sent to the receiver.
MSRSCORE http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode measure scoring Indicates how the calculation is performed for the eMeasure (e.g., proportion, continuous variable, ratio)
MSRSET http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode health quality measure care setting Location(s) in which care being measured is rendered Usage Note: MSRSET is used rather than RoleCode because the setting applies to what is being measured, as opposed to participating directly in the health quality measure documantion itself).
MSRTOPIC http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode health quality measure topic type health quality measure topic type
MSRTP http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode measurement period The time period for which the eMeasure applies.
MSRTYPE http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode measure type Indicates whether the eMeasure is used to examine a process or an outcome over time (e.g., Structure, Process, Outcome).
RAT http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode rationale Succinct statement of the need for the measure. Usually includes statements pertaining to Importance criterion: impact, gap in care and evidence.
REF http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode reference Identifies bibliographic citations or references to clinical practice guidelines, sources of evidence, or other relevant materials supporting the intent and rationale of the eMeasure.
SDE http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode supplemental data elements Comparison of results across strata can be used to show where disparities exist or where there is a need to expose differences in results. For example, Centers for Medicare & Medicaid Services (CMS) in the U.S. defines four required Supplemental Data Elements (payer, ethnicity, race, and gender), which are variables used to aggregate data into various subgroups. Additional supplemental data elements required for risk adjustment or other purposes of data aggregation can be included in the Supplemental Data Element section.
STRAT http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode stratification Describes the strata for which the measure is to be evaluated. There are three examples of reasons for stratification based on existing work. These include: (1) evaluate the measure based on different age groupings within the population described in the measure (e.g., evaluate the whole [age 14-25] and each sub-stratum [14-19] and [20-25]); (2) evaluate the eMeasure based on either a specific condition, a specific discharge location, or both; (3) evaluate the eMeasure based on different locations within a facility (e.g., evaluate the overall rate for all intensive care units and also some strata include additional findings [specific birth weights for neonatal intensive care units]).
TRANF http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode transmission format Can be a URL or hyperlinks that link to the transmission formats that are specified for a particular reporting program.
USE http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode notice of use Usage notes.
TIME_ABSOLUTE http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode absolute time sequence A sequence of values in the "absolute" "absolute" time domain. This is the same time domain that all HL7 timestamps use. It is time as measured by the Gregorian calendar
TIME_RELATIVE http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode relative time sequence A sequence of values in a "relative" "relative" time domain. The time is measured relative to the earliest effective time in the Observation Series containing this sequence.
REPRESENTATIVE_BEAT http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode ECG representative beat waveforms This Observation Series type contains waveforms of a "representative beat" "representative beat" (a.k.a. "median beat" "median beat" or "average beat"). "average beat"). The waveform samples are measured in relative time, relative to the beginning of the beat as defined by the Observation Series effective time. The waveforms are not directly acquired from the subject, but rather algorithmically derived from the "rhythm" "rhythm" waveforms.
RHYTHM http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode ECG rhythm waveforms This Observation type contains ECG "rhythm" "rhythm" waveforms. The waveform samples are measured in absolute time (a.k.a. "subject time" "subject time" or "effective time"). "effective time"). These waveforms are usually "raw" "raw" with some minimal amount of noise reduction and baseline filtering applied.
_PatientImmunizationRelatedObservationType http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode PatientImmunizationRelatedObservationType Description: Reporting codes that are related to an immunization event.
CLSSRM http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode classroom Description: The class room associated with the patient during the immunization event.
GRADE http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode grade Description: The school grade or level the patient was in when immunized.
SCHL http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode school Description: The school the patient attended when immunized.
SCHLDIV http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode school division Description: The school division or district associated with the patient during the immunization event.
TEACHER http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode teacher Description: The patient's teacher when immunized.
DENEX http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode denominator exclusions Criteria which specify subjects who should be removed from the eMeasure population and denominator before determining if numerator criteria are met. Denominator exclusions are used in proportion and ratio measures to help narrow the denominator.
DENEXCEP http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode denominator exceptions Criteria which specify the removal of a subject, procedure or unit of measurement from the denominator, only if the numerator criteria are not met. Denominator exceptions allow for adjustment of the calculated score for those providers with higher risk populations. Denominator exceptions are used only in proportion eMeasures. They are not appropriate for ratio or continuous variable eMeasures. Denominator exceptions allow for the exercise of clinical judgment and should be specifically defined where capturing the information in a structured manner fits the clinical workflow. Generic denominator exception reasons used in proportion eMeasures fall into three general categories: Medical reasons Patient (or subject) reasons System reasons
DENOM http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode denominator Criteria for specifying the entities to be evaluated by a specific quality measure, based on a shared common set of characteristics (within a specific measurement set to which a given measure belongs). The denominator can be the same as the initial population, or it may be a subset of the initial population to further constrain it for the purpose of the eMeasure. Different measures within an eMeasure set may have different denominators. Continuous Variable eMeasures do not have a denominator, but instead define a measure population.
IPOP http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode initial population Criteria for specifying the entities to be evaluated by a specific quality measure, based on a shared common set of characteristics (within a specific measurement set to which a given measure belongs).
IPPOP http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode initial patient population Criteria for specifying the patients to be evaluated by a specific quality measure, based on a shared common set of characteristics (within a specific measurement set to which a given measure belongs). Details often include information based upon specific age groups, diagnoses, diagnostic and procedure codes, and enrollment periods.
MSROBS http://terminology.hl7.org/CodeSystem/v3-ActCode measure observation Defines the observation to be performed for each patient or event in the measure population. Measure observations for each case in the population are aggregated to determine the overall measure score for the population. Examples: the median time from arrival in the Emergency Room to departure the median time from decision to admit to a hospital to the actual admission for Emergency Room patients
MSRPOPL http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode measure population Criteria for specifying the measure population as a narrative description (e.g., all patients seen in the Emergency Department during the measurement period). This is used only in continuous variable eMeasures.
MSRPOPLEX http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode measure population exclusions Criteria for specifying subjects who should be removed from the eMeasure's Initial Population and Measure Population. Measure Population Exclusions are used in Continuous Variable measures to help narrow the Measure Population before determining the value(s) of the continuous variable(s).
NUMER http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode numerator Criteria for specifying the processes or outcomes expected for each patient, procedure, or other unit of measurement defined in the denominator for proportion measures, or related to (but not directly derived from) the denominator for ratio measures (e.g., a numerator listing the number of central line blood stream infections and a denominator indicating the days per thousand of central line usage in a specific time period).
NUMEX http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode numerator exclusions Criteria for specifying instances that should not be included in the numerator data. (e.g., if the number of central line blood stream infections per 1000 catheter days were to exclude infections with a specific bacterium, that bacterium would be listed as a numerator exclusion). Numerator Exclusions are used only in ratio eMeasures.
PREFSTRENGTH http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode preference strength An observation about how important a preference is to the target of the preference.
ADVERSE_REACTION http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Adverse Reaction Indicates that the observation is of an unexpected negative occurrence in the subject suspected to result from the subject's exposure to one or more agents. Observation values would be the symptom resulting from the reaction.
ASSERTION http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Assertion Description:Refines classCode OBS to indicate an observation in which observation.value contains a finding or other nominalized statement, where the encoded information in Observation.value is not altered by Observation.code. For instance, observation.code="ASSERTION" observation.code="ASSERTION" and observation.value="fracture observation.value="fracture of femur present" present" is an assertion of a clinical finding of femur fracture.
CASESER http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode case seriousness criteria Definition:An observation that provides a characterization of the level of harm to an investigation subject as a result of a reaction or event.
CDIO http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode case disease imported observation An observation that states whether the disease was likely acquired outside the jurisdiction of observation, and if so, the nature of the inter-jurisdictional relationship. OpenIssue: This code could be moved to LOINC if it can be done before there are significant implemenations using it.
CRIT http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode criticality A clinical judgment as to the worst case result of a future exposure (including substance administration). When the worst case result is assessed to have a life-threatening or organ system threatening potential, it is considered to be of high criticality.
CTMO http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode case transmission mode observation An observation that states the mechanism by which disease was acquired by the living subject involved in the public health case. OpenIssue: This code could be moved to LOINC if it can be done before there are significant implemenations using it.
DX http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode ObservationDiagnosisTypes Includes all codes defining types of indications such as diagnosis, symptom and other indications such as contrast agents for lab tests.
ADMDX http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode admitting diagnosis Admitting diagnosis are the diagnoses documented for administrative purposes as the basis for a hospital admission.
DISDX http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode discharge diagnosis Discharge diagnosis are the diagnoses documented for administrative purposes as the time of hospital discharge.
INTDX http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode intermediate diagnosis Intermediate diagnoses are those diagnoses documented for administrative purposes during the course of a hospital stay.
NOI http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode nature of injury The type of injury that the injury coding specifies.
GISTIER http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode GIS tier Description: Accuracy determined as per the GIS tier code system.
HHOBS http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode household situation observation Indicates that the observation is of a person’s living situation in a household including the household composition and circumstances.
ISSUE http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode detected issue There is a clinical issue for the therapy that makes continuation of the therapy inappropriate. Open Issue: The definition of this code does not correctly represent the concept space of its specializations (children)
NAT http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Insufficient authorization The requesting party has insufficient authorization to invoke the interaction.
SUPPRESSED http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode record suppressed Description: One or more records in the query response have been suppressed due to consent or privacy restrictions.
VALIDAT http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode validation issue Description:The specified element did not pass business-rule validation.
KEY204 http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Unknown key identifier The ID of the patient, order, etc., was not found. Used for transactions other than additions, e.g. transfer of a non-existent patient.
KEY205 http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Duplicate key identifier The ID of the patient, order, etc., already exists. Used in response to addition transactions (Admit, New Order, etc.).
COMPLY http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Compliance Alert There may be an issue with the patient complying with the intentions of the proposed therapy
DUPTHPY http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Duplicate Therapy Alert The proposed therapy appears to duplicate an existing therapy
DUPTHPCLS http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode duplicate therapeutic alass alert Description:The proposed therapy appears to have the same intended therapeutic benefit as an existing therapy, though the specific mechanisms of action vary.
DUPTHPGEN http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode duplicate generic alert Description:The proposed therapy appears to have the same intended therapeutic benefit as an existing therapy and uses the same mechanisms of action as the existing therapy.
ABUSE http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode commonly abused/misused alert Description:The proposed therapy is frequently misused or abused and therefore should be used with caution and/or monitoring.
FRAUD http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode potential fraud Description:The request is suspected to have a fraudulent basis.
PLYDOC http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Poly-orderer Alert A similar or identical therapy was recently ordered by a different practitioner.
PLYPHRM http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Poly-supplier Alert This patient was recently supplied a similar or identical therapy from a different pharmacy or supplier.
DOSE http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Dosage problem Proposed dosage instructions for therapy differ from standard practice.
DOSECOND http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode dosage-condition alert Description:Proposed dosage is inappropriate due to patient's medical condition.
DOSEDUR http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Dose-Duration Alert Proposed length of therapy differs from standard practice.
DOSEDURH http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Dose-Duration High Alert Proposed length of therapy is longer than standard practice
DOSEDURHIND http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Dose-Duration High for Indication Alert Proposed length of therapy is longer than standard practice for the identified indication or diagnosis
DOSEDURL http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Dose-Duration Low Alert Proposed length of therapy is shorter than that necessary for therapeutic effect
DOSEDURLIND http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Dose-Duration Low for Indication Alert Proposed length of therapy is shorter than standard practice for the identified indication or diagnosis
DOSEH http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode High Dose Alert Proposed dosage exceeds standard practice
DOSEHINDA http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode High Dose for Age Alert Proposed dosage exceeds standard practice for the patient's age
DOSEHIND http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode High Dose for Indication Alert High Dose for Indication Alert
DOSEHINDSA http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode High Dose for Height/Surface Area Alert Proposed dosage exceeds standard practice for the patient's height or body surface area
DOSEHINDW http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode High Dose for Weight Alert Proposed dosage exceeds standard practice for the patient's weight
DOSEIVL http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Dose-Interval Alert Proposed dosage interval/timing differs from standard practice
DOSEIVLIND http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Dose-Interval for Indication Alert Proposed dosage interval/timing differs from standard practice for the identified indication or diagnosis
DOSEL http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Low Dose Alert Proposed dosage is below suggested therapeutic levels
DOSELINDA http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Low Dose for Age Alert Proposed dosage is below suggested therapeutic levels for the patient's age
DOSELIND http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Low Dose for Indication Alert Low Dose for Indication Alert
DOSELINDSA http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Low Dose for Height/Surface Area Alert Proposed dosage is below suggested therapeutic levels for the patient's height or body surface area
DOSELINDW http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Low Dose for Weight Alert Proposed dosage is below suggested therapeutic levels for the patient's weight
MDOSE http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode maximum dosage reached Description:The maximum quantity of this drug allowed to be administered within a particular time-range (month, year, lifetime) has been reached or exceeded.
OBSA http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Observation Alert Proposed therapy may be inappropriate or contraindicated due to conditions or characteristics of the patient
AGE http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Age Alert Proposed therapy may be inappropriate or contraindicated due to patient age
ADALRT http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode adult alert Proposed therapy is outside of the standard practice for an adult patient.
GEALRT http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode geriatric alert Proposed therapy is outside of standard practice for a geriatric patient.
PEALRT http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode pediatric alert Proposed therapy is outside of the standard practice for a pediatric patient.
COND http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Condition Alert Proposed therapy may be inappropriate or contraindicated due to an existing/recent patient condition or diagnosis
HGHT http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode HGHT
LACT http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Lactation Alert Proposed therapy may be inappropriate or contraindicated when breast-feeding
PREG http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Pregnancy Alert Proposed therapy may be inappropriate or contraindicated during pregnancy
WGHT http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode WGHT
CREACT http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode common reaction alert Description:Proposed therapy may be inappropriate or contraindicated because of a common but non-patient specific reaction to the product. Example:There is no record of a specific sensitivity for the patient, but the presence of the sensitivity is common and therefore caution is warranted.
GEN http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Genetic Alert Proposed therapy may be inappropriate or contraindicated due to patient genetic indicators.
GEND http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Gender Alert Proposed therapy may be inappropriate or contraindicated due to patient gender.
LAB http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Lab Alert Proposed therapy may be inappropriate or contraindicated due to recent lab test results
REACT http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Reaction Alert Proposed therapy may be inappropriate or contraindicated based on the potential for a patient reaction to the proposed product
ALGY http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Allergy Alert Proposed therapy may be inappropriate or contraindicated because of a recorded patient allergy to the proposed product. (Allergies are immune based reactions.)
INT http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Intolerance Alert Proposed therapy may be inappropriate or contraindicated because of a recorded patient intolerance to the proposed product. (Intolerances are non-immune based sensitivities.)
RREACT http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Related Reaction Alert Proposed therapy may be inappropriate or contraindicated because of a potential patient reaction to a cross-sensitivity related product.
RALG http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Related Allergy Alert Proposed therapy may be inappropriate or contraindicated because of a recorded patient allergy to a cross-sensitivity related product. (Allergies are immune based reactions.)
RAR http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Related Prior Reaction Alert Proposed therapy may be inappropriate or contraindicated because of a recorded prior adverse reaction to a cross-sensitivity related product.
RINT http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Related Intolerance Alert Proposed therapy may be inappropriate or contraindicated because of a recorded patient intolerance to a cross-sensitivity related product. (Intolerances are non-immune based sensitivities.)
BUS http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode business constraint violation Description:A local business rule relating multiple elements has been violated.
CODE_INVAL http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode code is not valid Description:The specified code is not valid against the list of codes allowed for the element.
CODE_DEPREC http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode code has been deprecated Description:The specified code has been deprecated and should no longer be used. Select another code from the code system.
FORMAT http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode invalid format Description:The element does not follow the formatting or type rules defined for the field.
ILLEGAL http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode illegal Description:The request is missing elements or contains elements which cause it to not meet the legal standards for actioning.
LEN_RANGE http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode length out of range Description:The length of the data specified falls out of the range defined for the element.
LEN_LONG http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode length is too long Description:The length of the data specified is greater than the maximum length defined for the element.
LEN_SHORT http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode length is too short Description:The length of the data specified is less than the minimum length defined for the element.
MISSCOND http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode conditional element missing Description:The specified element must be specified with a non-null value under certain conditions. In this case, the conditions are true but the element is still missing or null.
MISSMAND http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode mandatory element missing Description:The specified element is mandatory and was not included in the instance.
NODUPS http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode duplicate values are not permitted Description:More than one element with the same value exists in the set. Duplicates not permission in this set in a set.
NOPERSIST http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode element will not be persisted Description: Element in submitted message will not persist in data storage based on detected issue.
REP_RANGE http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode repetitions out of range Description:The number of repeating elements falls outside the range of the allowed number of repetitions.
MAXOCCURS http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode repetitions above maximum Description:The number of repeating elements is above the maximum number of repetitions allowed.
MINOCCURS http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode repetitions below minimum Description:The number of repeating elements is below the minimum number of repetitions allowed.
KEY206 http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode non-matching identification Description: Metadata associated with the identification (e.g. name or gender) does not match the identification being verified.
OBSOLETE http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode obsolete record returned Description: One or more records in the query response have a status of 'obsolete'.
FOOD http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Food Interaction Alert Proposed therapy may interact with certain foods
TPROD http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Therapeutic Product Alert Proposed therapy may interact with an existing or recent therapeutic product
DRG http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Drug Interaction Alert Proposed therapy may interact with an existing or recent drug therapy
NHP http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Natural Health Product Alert Proposed therapy may interact with existing or recent natural health product therapy
NONRX http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Non-Prescription Interaction Alert Proposed therapy may interact with a non-prescription drug (e.g. alcohol, tobacco, Aspirin)
PREVINEF http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode previously ineffective Definition:The same or similar treatment has previously been attempted with the patient without achieving a positive effect.
DACT http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode drug action detected issue Description:Proposed therapy may be contraindicated or ineffective based on an existing or recent drug therapy.
TIME http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode timing detected issue Description:Proposed therapy may be inappropriate or ineffective based on the proposed start or end time.
ALRTENDLATE http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode end too late alert Definition:Proposed therapy may be inappropriate or ineffective because the end of administration is too close to another planned therapy.
ALRTSTRTLATE http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode start too late alert Definition:Proposed therapy may be inappropriate or ineffective because the start of administration is too late after the onset of the condition.
ENDLATE http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode End Too Late Alert Proposed therapy may be inappropriate or ineffective because the end of administration is too close to another planned therapy
STRTLATE http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Start Too Late Alert Proposed therapy may be inappropriate or ineffective because the start of administration is too late after the onset of the condition
ALLDONE http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode already performed Definition:The requested action has already been performed and so this request has no effect
FULFIL http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode fulfillment alert Definition:The therapy being performed is in some way out of alignment with the requested therapy.
NOTACTN http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode no longer actionable Definition:The status of the request being fulfilled has changed such that it is no longer actionable. This may be because the request has expired, has already been completely fulfilled or has been otherwise stopped or disabled. (Not used for 'suspended' orders.)
NOTEQUIV http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode not equivalent alert Definition:The therapy being performed is not sufficiently equivalent to the therapy which was requested.
NOTEQUIVGEN http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode not generically equivalent alert Definition:The therapy being performed is not generically equivalent (having the identical biological action) to the therapy which was requested.
NOTEQUIVTHER http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode not therapeutically equivalent alert Definition:The therapy being performed is not therapeutically equivalent (having the same overall patient effect) to the therapy which was requested.
TIMING http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode event timing incorrect alert Definition:The therapy is being performed at a time which diverges from the time the therapy was requested
INTERVAL http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode outside requested time Definition:The therapy action is being performed outside the bounds of the time period requested
MINFREQ http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode too soon within frequency based on the usage Definition:The therapy action is being performed too soon after the previous occurrence based on the requested frequency
HELD http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode held/suspended alert Definition:There should be no actions taken in fulfillment of a request that has been held or suspended.
TOOLATE http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Refill Too Late Alert The patient is receiving a subsequent fill significantly later than would be expected based on the amount previously supplied and the therapy dosage instructions
TOOSOON http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Refill Too Soon Alert The patient is receiving a subsequent fill significantly earlier than would be expected based on the amount previously supplied and the therapy dosage instructions
HISTORIC http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode record recorded as historical Description: While the record was accepted in the repository, there is a more recent version of a record of this type.
PATPREF http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode violates stated preferences Definition:The proposed therapy goes against preferences or consent constraints recorded in the patient's record.
PATPREFALT http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode violates stated preferences, alternate available Definition:The proposed therapy goes against preferences or consent constraints recorded in the patient's record. An alternate therapy meeting those constraints is available.
KSUBJ http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode knowledge subject Categorization of types of observation that capture the main clinical knowledge subject which may be a medication, a laboratory test, a disease.
KSUBT http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode knowledge subtopic Categorization of types of observation that capture a knowledge subtopic which might be treatment, etiology, or prognosis.
OINT http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode intolerance Hypersensitivity resulting in an adverse reaction upon exposure to an agent.
ALG http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Allergy Hypersensitivity to an agent caused by an immunologic response to an initial exposure
DALG http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Drug Allergy An allergy to a pharmaceutical product.
EALG http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Environmental Allergy An allergy to a substance other than a drug or a food. E.g. Latex, pollen, etc.
FALG http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Food Allergy An allergy to a substance generally consumed for nutritional purposes.
DINT http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Drug Intolerance Hypersensitivity resulting in an adverse reaction upon exposure to a drug.
DNAINT http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Drug Non-Allergy Intolerance Hypersensitivity to an agent caused by a mechanism other than an immunologic response to an initial exposure
EINT http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Environmental Intolerance Hypersensitivity resulting in an adverse reaction upon exposure to environmental conditions.
ENAINT http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Environmental Non-Allergy Intolerance Hypersensitivity to an agent caused by a mechanism other than an immunologic response to an initial exposure
FINT http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Food Intolerance Hypersensitivity resulting in an adverse reaction upon exposure to food.
FNAINT http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Food Non-Allergy Intolerance Hypersensitivity to an agent caused by a mechanism other than an immunologic response to an initial exposure
NAINT http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Non-Allergy Intolerance Hypersensitivity to an agent caused by a mechanism other than an immunologic response to an initial exposure
SEV http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode Severity Observation A subjective evaluation of the seriousness or intensity associated with another observation.
FDACOATING http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode coating FDA label coating
FDACOLOR http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode color FDA label color
FDAIMPRINTCD http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode imprint code FDA label imprint code
FDALOGO http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode logo FDA label logo
FDASCORING http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode scoring FDA label scoring
FDASHAPE http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode shape FDA label shape
FDASIZE http://hl7.org/fhir/v3/ActCode http://terminology.hl7.org/CodeSystem/v3-ActCode size FDA label size
1-8 http://loinc.org Acyclovir [Susceptibility]
10-9 http://loinc.org Amdinocillin [Susceptibility] by Serum bactericidal titer
100-8 http://loinc.org Cefoperazone [Susceptibility] by Minimum inhibitory concentration (MIC)
1000-9 http://loinc.org DBG Ab [Presence] in Serum or Plasma from Blood product unit
10000-8 http://loinc.org R wave duration in lead AVR
10001-6 http://loinc.org R wave duration in lead I
10002-4 http://loinc.org R wave duration in lead II
10003-2 http://loinc.org R wave duration in lead III
10004-0 http://loinc.org R wave duration in lead V1
10005-7 http://loinc.org R wave duration in lead V2
10006-5 http://loinc.org R wave duration in lead V3
10007-3 http://loinc.org R wave duration in lead V4
10008-1 http://loinc.org R wave duration in lead V5
10009-9 http://loinc.org R wave duration in lead V6
1001-7 http://loinc.org DBG Ab [Presence] in Serum or Plasma from donor Donor
10010-7 http://loinc.org R' wave amplitude in lead AVF
10011-5 http://loinc.org R' wave amplitude in lead AVL
10012-3 http://loinc.org R' wave amplitude in lead AVR
10013-1 http://loinc.org R' wave amplitude in lead I
10014-9 http://loinc.org R' wave amplitude in lead II
10015-6 http://loinc.org R' wave amplitude in lead III
10016-4 http://loinc.org R' wave amplitude in lead V1
10017-2 http://loinc.org R' wave amplitude in lead V2
10018-0 http://loinc.org R' wave amplitude in lead V3
10019-8 http://loinc.org R' wave amplitude in lead V4
1002-5 http://loinc.org DBG Ab [Presence] in Serum or Plasma
10020-6 http://loinc.org R' wave amplitude in lead V5
10021-4 http://loinc.org R' wave amplitude in lead V6
10022-2 http://loinc.org R' wave duration in lead AVF
10023-0 http://loinc.org R' wave duration in lead AVL
10024-8 http://loinc.org R' wave duration in lead AVR
10025-5 http://loinc.org R' wave duration in lead I
10026-3 http://loinc.org R' wave duration in lead II
10027-1 http://loinc.org R' wave duration in lead III
10028-9 http://loinc.org R' wave duration in lead V1
10029-7 http://loinc.org R' wave duration in lead V2
1003-3 http://loinc.org Indirect antiglobulin test.complement specific reagent [Presence] in Serum or Plasma
10030-5 http://loinc.org R' wave duration in lead V3
10031-3 http://loinc.org R' wave duration in lead V4
10032-1 http://loinc.org R' wave duration in lead V5
10033-9 http://loinc.org R' wave duration in lead V6
10034-7 http://loinc.org S wave amplitude in lead AVF
10035-4 http://loinc.org S wave amplitude in lead AVL
10036-2 http://loinc.org S wave amplitude in lead AVR
10037-0 http://loinc.org S wave amplitude in lead I
10038-8 http://loinc.org S wave amplitude in lead II
10039-6 http://loinc.org S wave amplitude in lead III
1004-1 http://loinc.org Direct antiglobulin test.complement specific reagent [Presence] on Red Blood Cells
10040-4 http://loinc.org S wave amplitude in lead V1
10041-2 http://loinc.org S wave amplitude in lead V2
10042-0 http://loinc.org S wave amplitude in lead V3
10043-8 http://loinc.org S wave amplitude in lead V4
10044-6 http://loinc.org S wave amplitude in lead V5
10045-3 http://loinc.org S wave amplitude in lead V6
10046-1 http://loinc.org S wave duration in lead AVF
10047-9 http://loinc.org S wave duration in lead AVL
10048-7 http://loinc.org S wave duration in lead AVR
10049-5 http://loinc.org S wave duration in lead I
1005-8 http://loinc.org Indirect antiglobulin test.IgG specific reagent [Presence] in Serum or Plasma
10050-3 http://loinc.org S wave duration in lead II
10051-1 http://loinc.org S wave duration in lead III
10052-9 http://loinc.org S wave duration in lead V1
10053-7 http://loinc.org S wave duration in lead V2
10054-5 http://loinc.org S wave duration in lead V3
10055-2 http://loinc.org S wave duration in lead V4
10056-0 http://loinc.org S wave duration in lead V5
10057-8 http://loinc.org S wave duration in lead V6
10058-6 http://loinc.org S' wave amplitude in lead AVF
10059-4 http://loinc.org S' wave amplitude in lead AVL
1006-6 http://loinc.org Direct antiglobulin test.IgG specific reagent [Interpretation] on Red Blood Cells
10060-2 http://loinc.org S' wave amplitude in lead AVR
10061-0 http://loinc.org S' wave amplitude in lead I
10062-8 http://loinc.org S' wave amplitude in lead II
10063-6 http://loinc.org S' wave amplitude in lead III
10064-4 http://loinc.org S' wave amplitude in lead V1
10065-1 http://loinc.org S' wave amplitude in lead V2
10066-9 http://loinc.org S' wave amplitude in lead V3
10067-7 http://loinc.org S' wave amplitude in lead V4
10068-5 http://loinc.org S' wave amplitude in lead V5
10069-3 http://loinc.org S' wave amplitude in lead V6
1007-4 http://loinc.org Direct antiglobulin test.poly specific reagent [Presence] on Red Blood Cells
10070-1 http://loinc.org S' wave duration in lead AVF
10071-9 http://loinc.org S' wave duration in lead AVL
10072-7 http://loinc.org S' wave duration in lead AVR
10073-5 http://loinc.org S' wave duration in lead I
10074-3 http://loinc.org S' wave duration in lead II
10075-0 http://loinc.org S' wave duration in lead III
10076-8 http://loinc.org S' wave duration in lead V1
10077-6 http://loinc.org S' wave duration in lead V2
10078-4 http://loinc.org S' wave duration in lead V3
10079-2 http://loinc.org S' wave duration in lead V4
1008-2 http://loinc.org Indirect antiglobulin test.poly specific reagent [Presence] in Serum or Plasma
10080-0 http://loinc.org S' wave duration in lead V5
10081-8 http://loinc.org S' wave duration in lead V6
10082-6 http://loinc.org ST initial amplitude 6 ms in lead AVF
10083-4 http://loinc.org ST initial amplitude 6 ms in lead AVL
10084-2 http://loinc.org ST initial amplitude 6 ms in lead AVR
10085-9 http://loinc.org ST initial amplitude 6 ms in lead I
10086-7 http://loinc.org ST initial amplitude 6 ms in lead II
10087-5 http://loinc.org ST initial amplitude 6 ms in lead III
10088-3 http://loinc.org ST initial amplitude 6 ms in lead V1
10089-1 http://loinc.org ST initial amplitude 6 ms in lead V2
1009-0 http://loinc.org Deprecated Direct antiglobulin test.poly specific reagent [Presence] on Red Blood Cells
10090-9 http://loinc.org ST initial amplitude 6 ms in lead V3
10091-7 http://loinc.org ST initial amplitude 6 ms in lead V4
10092-5 http://loinc.org ST initial amplitude 6 ms in lead V5
10093-3 http://loinc.org ST initial amplitude 6 ms in lead V6
10094-1 http://loinc.org ST slope in lead AVF
10095-8 http://loinc.org ST slope in lead AVL
10096-6 http://loinc.org ST slope in lead AVR
10097-4 http://loinc.org ST slope in lead I
10098-2 http://loinc.org ST slope in lead II
10099-0 http://loinc.org ST slope in lead III
101-6 http://loinc.org Cefoperazone [Susceptibility] by Disk diffusion (KB)
1010-8 http://loinc.org Ew E sup(w) Ab [Presence] in Serum or Plasma from Blood product unit
10100-6 http://loinc.org ST slope in lead V1
10101-4 http://loinc.org ST slope in lead V2
10102-2 http://loinc.org ST slope in lead V3
10103-0 http://loinc.org ST slope in lead V4
10104-8 http://loinc.org ST slope in lead V5
10105-5 http://loinc.org ST slope in lead V6
10106-3 http://loinc.org ST wave end displacement in lead AVF
10107-1 http://loinc.org ST wave end displacement in lead AVL
10108-9 http://loinc.org ST wave end displacement in lead AVR
10109-7 http://loinc.org ST wave end displacement in lead I
1011-6 http://loinc.org Ew E sup(w) Ab [Presence] in Serum or Plasma from donor Donor
10110-5 http://loinc.org ST wave end displacement in lead II
10111-3 http://loinc.org ST wave end displacement in lead III
10112-1 http://loinc.org ST wave end displacement in lead V1
10113-9 http://loinc.org ST wave end displacement in lead V2
10114-7 http://loinc.org ST wave end displacement in lead V3
10115-4 http://loinc.org ST wave end displacement in lead V4
10116-2 http://loinc.org ST wave end displacement in lead V5
10117-0 http://loinc.org ST wave end displacement in lead V6
10118-8 http://loinc.org ST wave mid displacement in lead AVF
10119-6 http://loinc.org ST wave mid displacement in lead AVL
1012-4 http://loinc.org Ew E sup(w) Ab [Presence] in Serum or Plasma
10120-4 http://loinc.org ST wave mid displacement in lead AVR
10121-2 http://loinc.org ST wave mid displacement in lead I
10122-0 http://loinc.org ST wave mid displacement in lead II
10123-8 http://loinc.org ST wave mid displacement in lead III
10124-6 http://loinc.org ST wave mid displacement in lead V1
10125-3 http://loinc.org ST wave mid displacement in lead V2
10126-1 http://loinc.org ST wave mid displacement in lead V3
10127-9 http://loinc.org ST wave mid displacement in lead V4
10128-7 http://loinc.org ST wave mid displacement in lead V5
10129-5 http://loinc.org ST wave mid displacement in lead V6
1013-2 http://loinc.org Ew E sup(w) Ag [Presence] on Red Blood Cells from Blood product unit
10130-3 http://loinc.org T' wave amplitude in lead AVF
10131-1 http://loinc.org T' wave amplitude in lead AVL
10132-9 http://loinc.org T' wave amplitude in lead AVR
10133-7 http://loinc.org T' wave amplitude in lead I
10134-5 http://loinc.org T' wave amplitude in lead II
10135-2 http://loinc.org T' wave amplitude in lead III
10136-0 http://loinc.org T' wave amplitude in lead V1
10137-8 http://loinc.org T' wave amplitude in lead V2
10138-6 http://loinc.org T' wave amplitude in lead V3
10139-4 http://loinc.org T' wave amplitude in lead V4
1014-0 http://loinc.org Ew E sup(w) Ag [Presence] on Red Blood Cells from donor Donor
10140-2 http://loinc.org T' wave amplitude in lead V5
10141-0 http://loinc.org T' wave amplitude in lead V6
10142-8 http://loinc.org T wave amplitude in lead AVF
10143-6 http://loinc.org T wave amplitude in lead AVL
10144-4 http://loinc.org T wave amplitude in lead AVR
10145-1 http://loinc.org T wave amplitude in lead I
10146-9 http://loinc.org T wave amplitude in lead II
10147-7 http://loinc.org T wave amplitude in lead III
10148-5 http://loinc.org T wave amplitude in lead V1
10149-3 http://loinc.org T wave amplitude in lead V2
1015-7 http://loinc.org Ew E sup(w) Ag [Presence] on Red Blood Cells
10150-1 http://loinc.org T wave amplitude in lead V3
10151-9 http://loinc.org T wave amplitude in lead V4
10152-7 http://loinc.org T wave amplitude in lead V5
10153-5 http://loinc.org T wave amplitude in lead V6
10154-3 http://loinc.org Chief complaint Narrative - Reported
10155-0 http://loinc.org History of allergies, reported
10156-8 http://loinc.org History of Childhood diseases Narrative
10157-6 http://loinc.org History of family member diseases Narrative
10158-4 http://loinc.org History of Functional status Narrative
10159-2 http://loinc.org History of Industrial exposure Narrative
1016-5 http://loinc.org E Ab [Presence] in Serum or Plasma from Blood product unit
10160-0 http://loinc.org History of Medication use Narrative
10161-8 http://loinc.org History of Occupational exposure Narrative
10162-6 http://loinc.org History of pregnancies Narrative
10163-4 http://loinc.org History of pregnancies
10164-2 http://loinc.org History of Present illness Narrative
10165-9 http://loinc.org Deprecated History of psychiatric symptoms and diseases Narrative
10166-7 http://loinc.org History of Social function Narrative
10167-5 http://loinc.org History of Surgical procedures Narrative
10168-3 http://loinc.org History of Cardiovascular system disorders Narrative
10169-1 http://loinc.org History of Ear disorders Narrative
1017-3 http://loinc.org E Ab [Presence] in Serum or Plasma from donor Donor
10170-9 http://loinc.org History of Endocrine system disorders Narrative
10171-7 http://loinc.org History of Eyes disorders Narrative
10172-5 http://loinc.org History of Hematologic system disorders Narrative
10173-3 http://loinc.org History of Musculoskeletal system disorders Narrative
10174-1 http://loinc.org History of Nose disorders Narrative
10175-8 http://loinc.org History of Oral cavity disorders Narrative
10176-6 http://loinc.org History of Reproductive system disorders Narrative
10177-4 http://loinc.org History of Respiratory system disorders Narrative
10178-2 http://loinc.org History of Skin disorders Narrative
10179-0 http://loinc.org History of Throat and Neck disorders Narrative
1018-1 http://loinc.org E Ab [Presence] in Serum or Plasma
10180-8 http://loinc.org History of Throat and Neck disorders
10181-6 http://loinc.org History of Urinary tract disorders Narrative
10182-4 http://loinc.org History of Travel Narrative
10183-2 http://loinc.org Hospital discharge medications Narrative
10184-0 http://loinc.org Hospital discharge physical findings Narrative
10185-7 http://loinc.org Hospital discharge procedures Narrative
10186-5 http://loinc.org Identifying information Narrative Observed
10187-3 http://loinc.org Review of systems Narrative - Reported
10188-1 http://loinc.org Review of systems overview Narrative - Reported
10189-9 http://loinc.org Review of systems overview - Reported
1019-9 http://loinc.org E Ag [Presence] on Red Blood Cells from Blood product unit
10190-7 http://loinc.org Mental status Narrative
10191-5 http://loinc.org Physical findings of Abdomen Narrative
10192-3 http://loinc.org Physical findings of Back Narrative
10193-1 http://loinc.org Physical findings of Breasts Narrative
10194-9 http://loinc.org Physical findings of Neurologic deep tendon reflexes Narrative
10195-6 http://loinc.org Physical findings of Ear Narrative
10196-4 http://loinc.org Physical findings of Extremities Narrative
10197-2 http://loinc.org Physical findings of Eye Narrative
10198-0 http://loinc.org Physical findings of Genitourinary tract Narrative
10199-8 http://loinc.org Physical findings of Head Narrative
102-4 http://loinc.org Cefoperazone [Susceptibility] by Serum bactericidal titer
1020-7 http://loinc.org E Ag [Presence] on Red Blood Cells from donor Donor
10200-4 http://loinc.org Physical findings of Heart Narrative
10201-2 http://loinc.org Physical findings of Mouth and Throat and Teeth Narrative
10202-0 http://loinc.org Physical findings of Nervous system Narrative
10203-8 http://loinc.org Physical findings of Nose Narrative
10204-6 http://loinc.org Physical findings of Pelvis Narrative
10205-3 http://loinc.org Physical findings of Rectum Narrative
10206-1 http://loinc.org Physical findings of Skin Narrative
10207-9 http://loinc.org Physical findings of Thorax and Lungs Narrative
10208-7 http://loinc.org Physical findings of Vessels Narrative
10209-5 http://loinc.org Physical findings of Neurologic balance and Coordination Narrative
1021-5 http://loinc.org E Ag [Presence] on Red Blood Cells
10210-3 http://loinc.org Physical findings of General status Narrative
10211-1 http://loinc.org Physical findings of Sense of touch Narrative
10212-9 http://loinc.org Physical findings of Strength Narrative
10213-7 http://loinc.org Surgical operation note anesthesia Narrative
10214-5 http://loinc.org Surgical operation note anesthesia duration
10215-2 http://loinc.org Surgical operation note findings Narrative
10216-0 http://loinc.org Surgical operation note fluids Narrative
10217-8 http://loinc.org Surgical operation note indications [Interpretation] Narrative
10218-6 http://loinc.org Surgical operation note postoperative diagnosis Narrative
10219-4 http://loinc.org Surgical operation note preoperative diagnosis Narrative
1022-3 http://loinc.org Fy sup(a) Ab [Presence] in Serum or Plasma from Blood product unit
10220-2 http://loinc.org Surgical operation note prep time duration
10221-0 http://loinc.org Surgical operation note specimens taken Narrative
10222-8 http://loinc.org Surgical operation note surgical complications [Interpretation] Narrative
10223-6 http://loinc.org Surgical operation note surgical procedure Narrative
10224-4 http://loinc.org Hemodynamic method special circumstances
10225-1 http://loinc.org Cardiac measurement device Institution inventory number
10226-9 http://loinc.org Oxygen content in Intravascular space
10227-7 http://loinc.org Cardiac measurement device Vendor model number
10228-5 http://loinc.org Cardiac measurement device Vendor serial number
10229-3 http://loinc.org Hemodynamic method Type of
1023-1 http://loinc.org Fy sup(a) Ab [Presence] in Serum or Plasma from donor Donor
10230-1 http://loinc.org Left ventricular Ejection fraction
10231-9 http://loinc.org Right ventricular Ejection fraction
10232-7 http://loinc.org Oxygen content in Aorta root
10233-5 http://loinc.org Oxygen content in Left atrium
10234-3 http://loinc.org Oxygen content in Right atrium
10235-0 http://loinc.org Oxygen content in High right atrium
10236-8 http://loinc.org Oxygen content in Low right atrium
10237-6 http://loinc.org Oxygen content in Mid right atrium
10238-4 http://loinc.org Oxygen content in Left ventricle
10239-2 http://loinc.org Oxygen content in Right ventricular outflow tract
1024-9 http://loinc.org Fy sup(a) Ab [Presence] in Serum or Plasma
10240-0 http://loinc.org Oxygen content in Right ventricle
10241-8 http://loinc.org Oxygen content in Coronary sinus
10242-6 http://loinc.org Oxygen content in Ductus arteriosus
10243-4 http://loinc.org Oxygen content in Inferior vena cava
10244-2 http://loinc.org Oxygen content in Left pulmonary artery
10245-9 http://loinc.org Oxygen content in Main pulmonary artery
10246-7 http://loinc.org Oxygen content in Right pulmonary artery
10247-5 http://loinc.org Oxygen content in Pulmonary wedge
10248-3 http://loinc.org Oxygen content in Superior vena cava
10249-1 http://loinc.org Heart rate device Institution inventory number
1025-6 http://loinc.org Fy sup(a) Ag [Presence] on Red Blood Cells from Blood product unit
10250-9 http://loinc.org Heart rate device Vendor model number
10251-7 http://loinc.org Heart rate device Vendor serial number
10252-5 http://loinc.org Biliary drain site
10253-3 http://loinc.org Type of Biliary drain
10254-1 http://loinc.org Type of Peritoneal drain
10255-8 http://loinc.org Type of Subarachnoid drain
10256-6 http://loinc.org Biliary drain Institution inventory number
10257-4 http://loinc.org Chest tube Institution inventory number
10258-2 http://loinc.org Enteral tube Institution inventory number
10259-0 http://loinc.org Gastrostomy tube Institution inventory number
1026-4 http://loinc.org Fy sup(a) Ag [Presence] on Red Blood Cells from donor Donor
10260-8 http://loinc.org GI tube Institution inventory number
10261-6 http://loinc.org Intravascular tube Institution inventory number
10262-4 http://loinc.org IO tube Institution inventory number
10263-2 http://loinc.org Nasogastric tube Institution inventory number
10264-0 http://loinc.org Oral tube Institution inventory number
10265-7 http://loinc.org Peritoneal drain Institution inventory number
10266-5 http://loinc.org Peritoneal tube Institution inventory number
10267-3 http://loinc.org Rate control device Institution inventory number
10268-1 http://loinc.org Stool collection device Institution inventory number
10269-9 http://loinc.org Subarachnoid drain Institution inventory number
1027-2 http://loinc.org Fy sup(a) Ag [Presence] on Red Blood Cells
10270-7 http://loinc.org Synovial drain Institution inventory number
10271-5 http://loinc.org Tube or drain Institution inventory number
10272-3 http://loinc.org Upper GI tube Institution inventory number
10273-1 http://loinc.org Bladder irrigation tube Institution inventory number
10274-9 http://loinc.org Urine tube Institution inventory number
10275-6 http://loinc.org Wound drain device Institution inventory number
10276-4 http://loinc.org Peritoneal drain site
10277-2 http://loinc.org Stool collection site
10278-0 http://loinc.org Subarachnoid drain site
10279-8 http://loinc.org Biliary drain Vendor model number
1028-0 http://loinc.org Fy sup(b) Ab [Presence] in Serum or Plasma from Blood product unit
10280-6 http://loinc.org Chest tube Vendor model number
10281-4 http://loinc.org Enteral tube Vendor model number
10282-2 http://loinc.org Gastrostomy tube Vendor model number
10283-0 http://loinc.org GI tube Vendor model number
10284-8 http://loinc.org Intravascular tube Vendor model number
10285-5 http://loinc.org IO tube Vendor model number
10286-3 http://loinc.org Nasogastric tube Vendor model number
10287-1 http://loinc.org Oral tube Vendor model number
10288-9 http://loinc.org Peritoneal drain Vendor model number
10289-7 http://loinc.org Peritoneal tube Vendor model number
1029-8 http://loinc.org Fy sup(b) Ab [Presence] in Serum or Plasma from donor Donor
10290-5 http://loinc.org Rate control device Vendor model number
10291-3 http://loinc.org Stool collection device Vendor model number
10292-1 http://loinc.org Subarachnoid drain Vendor model number
10293-9 http://loinc.org Synovial drain Vendor model number
10294-7 http://loinc.org Tube or drain Vendor model number
10295-4 http://loinc.org Upper GI tube Vendor model number
10296-2 http://loinc.org Bladder irrigation tube Vendor model number
10297-0 http://loinc.org Urine tube Vendor model number
10298-8 http://loinc.org Wound drain device Vendor model number
10299-6 http://loinc.org Biliary drain Vendor serial number
103-2 http://loinc.org Ceforanide [Susceptibility] by Minimum lethal concentration (MLC)
1030-6 http://loinc.org Fy sup(b) Ab [Presence] in Serum or Plasma
10300-2 http://loinc.org Chest tube Vendor serial number
10301-0 http://loinc.org Enteral tube Vendor serial number
10302-8 http://loinc.org Gastrostomy tube Vendor serial number
10303-6 http://loinc.org GI tube Vendor serial number
10304-4 http://loinc.org Intravascular tube Vendor serial number
10305-1 http://loinc.org IO tube Vendor serial number
10306-9 http://loinc.org Nasogastric tube Vendor serial number
10307-7 http://loinc.org Oral tube Vendor serial number
10308-5 http://loinc.org Peritoneal drain Vendor serial number
10309-3 http://loinc.org Peritoneal tube Vendor serial number
1031-4 http://loinc.org Fy sup(b) Ag [Presence] on Red Blood Cells from Blood product unit
10310-1 http://loinc.org Rate control device Vendor serial number
10311-9 http://loinc.org Stool collection device Vendor serial number
10312-7 http://loinc.org Subarachnoid drain Vendor serial number
10313-5 http://loinc.org Synovial drain Vendor serial number
10314-3 http://loinc.org Tube or drain Vendor serial number
10315-0 http://loinc.org Upper GI tube Vendor serial number
10316-8 http://loinc.org Bladder irrigation tube Vendor serial number
10317-6 http://loinc.org Urine tube Vendor serial number
10318-4 http://loinc.org Wound drain device Vendor serial number
10319-2 http://loinc.org Enema device Institution inventory number
1032-2 http://loinc.org Fy sup(b) Ag [Presence] on Red Blood Cells from donor Donor
10320-0 http://loinc.org Enema device Vendor model number
10321-8 http://loinc.org Enema device Vendor serial number
10322-6 http://loinc.org Potassium intake 24 hour
10323-4 http://loinc.org Wound drain fluid [Appearance] Lower GI tract
10324-2 http://loinc.org Breath rate device Institution inventory number
10325-9 http://loinc.org Breath rate device Vendor model number
10326-7 http://loinc.org Breath rate device Vendor serial number
10327-5 http://loinc.org Eosinophils/100 leukocytes in Sputum by Manual count
10328-3 http://loinc.org Lymphocytes/100 leukocytes in Cerebral spinal fluid by Manual count
10329-1 http://loinc.org Monocytes/100 leukocytes in Cerebral spinal fluid by Manual count
1033-0 http://loinc.org Fy sup(b) Ag [Presence] on Red Blood Cells
10330-9 http://loinc.org Monocytes/100 leukocytes in Body fluid by Manual count
10331-7 http://loinc.org Rh [Type] in Blood
10332-5 http://loinc.org Cortisol [Mass/volume] in Serum or Plasma --pre 250 ug corticotropin IM
10333-3 http://loinc.org Appearance of Cerebral spinal fluid
10334-1 http://loinc.org Cancer Ag 125 [Units/volume] in Serum or Plasma
10335-8 http://loinc.org Color of Cerebral spinal fluid
10336-6 http://loinc.org Gonadotropin peptide [Mass/volume] in Urine
10337-4 http://loinc.org Procollagen type I [Mass/volume] in Serum
10338-2 http://loinc.org Barbiturates [Mass/volume] in Serum or Plasma
10339-0 http://loinc.org Fluoxetine+Norfluoxetine [Mass/volume] in Serum or Plasma
1034-8 http://loinc.org Fetal cell screen [Interpretation] in Blood
10340-8 http://loinc.org Molindone [Mass/volume] in Serum or Plasma
10341-6 http://loinc.org Norpropoxyphene [Mass/volume] in Serum or Plasma
10342-4 http://loinc.org Sulfamethoxazole [Mass/volume] in Serum or Plasma
10343-2 http://loinc.org Temazepam [Mass/volume] in Serum or Plasma
10344-0 http://loinc.org Tranylcypromine [Mass/volume] in Serum or Plasma
10345-7 http://loinc.org Trihexyphenidyl [Mass/volume] in Urine
10346-5 http://loinc.org Hemoglobin A [Units/volume] in Blood by Electrophoresis
10347-3 http://loinc.org Babesia microti identified in Blood by Light microscopy
10348-1 http://loinc.org Bordetella parapertussis Ab [Presence] in Serum
10349-9 http://loinc.org Brucella sp Ab [Units/volume] in Serum
1035-5 http://loinc.org Fresh frozen plasma given [Volume]
10350-7 http://loinc.org Herpes simplex virus IgM Ab [Titer] in Serum by Immunoassay
10351-5 http://loinc.org HIV 1 RNA [Units/volume] (viral load) in Serum or Plasma by Probe with amplification
10352-3 http://loinc.org Bacteria identified in Genital specimen by Aerobe culture
10353-1 http://loinc.org Bacteria identified in Nose by Aerobe culture
10354-9 http://loinc.org Bacteria identified in Urethra by Culture
10355-6 http://loinc.org Microscopic observation [Identifier] in Bone marrow by Wright Giemsa stain
10356-4 http://loinc.org Deprecated Microscopic observation [Identifier] in Stool by Trichrome stain
10357-2 http://loinc.org Microscopic observation [Identifier] in Wound by Gram stain
10358-0 http://loinc.org Teichoate Ab [Titer] in Serum by Immune diffusion (ID)
10359-8 http://loinc.org Asialoganglioside GM1 IgM Ab [Titer] in Serum
1036-3 http://loinc.org G Ab [Presence] in Serum or Plasma from Blood product unit
10360-6 http://loinc.org DNA single strand IgG Ab [Units/volume] in Serum
10361-4 http://loinc.org DNA single strand IgM Ab [Units/volume] in Serum
10362-2 http://loinc.org Endomysium IgA Ab [Presence] in Serum
10363-0 http://loinc.org Barbiturates [Presence] in Unspecified specimen
10364-8 http://loinc.org Cotinine [Mass/mass] in Hair
10365-5 http://loinc.org Cotinine [Mass/volume] in Serum or Plasma
10366-3 http://loinc.org Cotinine [Mass/volume] in Urine
10367-1 http://loinc.org Ethanol [Mass/volume] in Gastric fluid
10368-9 http://loinc.org Lead [Mass/volume] in Capillary blood
10369-7 http://loinc.org Opiates [Mass/mass] in Hair
1037-1 http://loinc.org G Ab [Presence] in Serum or Plasma from donor Donor
10370-5 http://loinc.org Phencyclidine [Mass/mass] in Hair
10371-3 http://loinc.org Bite cells [Presence] in Blood by Light microscopy
10372-1 http://loinc.org Blister cells [Presence] in Blood by Light microscopy
10373-9 http://loinc.org Fragments [Presence] in Blood by Light microscopy
10374-7 http://loinc.org Helmet cells [Presence] in Blood by Light microscopy
10375-4 http://loinc.org Irregularly contracted cells [Presence] in Blood by Light microscopy
10376-2 http://loinc.org Oval macrocytes [Presence] in Blood by Light microscopy
10377-0 http://loinc.org Pencil cells [Presence] in Blood by Light microscopy
10378-8 http://loinc.org Polychromasia [Presence] in Blood by Light microscopy
10379-6 http://loinc.org Erythrocytes.dual population [Presence] in Blood by Light microscopy
1038-9 http://loinc.org G Ab [Presence] in Serum or Plasma
10380-4 http://loinc.org Stomatocytes [Presence] in Blood by Light microscopy
10381-2 http://loinc.org Target cells [Presence] in Blood by Light microscopy
10382-0 http://loinc.org A,B variant NOS Ag [Presence] on Red Blood Cells from Blood product unit
10383-8 http://loinc.org A,B variant NOS Ag [Presence] on Red Blood Cells from donor Donor
10384-6 http://loinc.org A,B variant NOS Ag [Presence] on Red Blood Cells
10385-3 http://loinc.org Albumin concentration given
10386-1 http://loinc.org Albumin given [Volume]
10387-9 http://loinc.org Autologous erythrocytes given [Volume]
10388-7 http://loinc.org Autologous whole blood given [Volume]
10389-5 http://loinc.org Blood product.other [Type]
1039-7 http://loinc.org G Ag [Presence] on Red Blood Cells from Blood product unit
10390-3 http://loinc.org Blood product special preparation [Type]
10391-1 http://loinc.org Cytomegalovirus immune globulin given [Volume]
10392-9 http://loinc.org Cryoprecipitate given [Volume]
10393-7 http://loinc.org Factor IX given [Type]
10394-5 http://loinc.org Factor IX given [Volume]
10395-2 http://loinc.org Factor VIII given [Type]
10396-0 http://loinc.org Factor VIII given [Volume]
10397-8 http://loinc.org Hepatitis B immune globulin given [Volume]
10398-6 http://loinc.org I Ag [Presence] on Red Blood Cells from Blood product unit
10399-4 http://loinc.org I Ag [Presence] on Red Blood Cells from donor Donor
104-0 http://loinc.org Ceforanide [Susceptibility] by Minimum inhibitory concentration (MIC)
1040-5 http://loinc.org G Ag [Presence] on Red Blood Cells from donor Donor
10400-0 http://loinc.org I Ag [Presence] on Red Blood Cells
10401-8 http://loinc.org Immune serum globulin given [Type]
10402-6 http://loinc.org Immune serum globulin given [Volume]
10403-4 http://loinc.org Inject immune serum globulin [Volume]
10404-2 http://loinc.org Inject Rh immune globulin [Volume]
10405-9 http://loinc.org Inject varicella zoster virus immune globulin [Volume]
10406-7 http://loinc.org little i Ag [Presence] on Red Blood Cells from Blood product unit
10407-5 http://loinc.org little i Ag [Presence] on Red Blood Cells from donor Donor
10408-3 http://loinc.org little i Ag [Presence] on Red Blood Cells
10409-1 http://loinc.org Pentaspan given [Volume]
1041-3 http://loinc.org G Ag [Presence] on Red Blood Cells
10410-9 http://loinc.org Plasma given [Type]
10411-7 http://loinc.org Plasma given [Volume]
10412-5 http://loinc.org Platelets given [Type]
10413-3 http://loinc.org Rh immune globulin given [Volume]
10414-1 http://loinc.org Transfuse albumin [Volume]
10415-8 http://loinc.org Transfuse blood exchange transfusion [Volume]
10416-6 http://loinc.org Transfuse blood product other [Volume]
10417-4 http://loinc.org Transfuse cryoprecipitate [Volume]
10418-2 http://loinc.org Transfuse factor IX [Volume]
10419-0 http://loinc.org Transfuse factor VIII [Volume]
1042-1 http://loinc.org H Ab [Presence] in Serum or Plasma from Blood product unit
10420-8 http://loinc.org Transfuse immune serum globulin [Volume]
10421-6 http://loinc.org Transfuse Pentaspan [Volume]
10422-4 http://loinc.org Transfuse plasma [Volume]
10423-2 http://loinc.org Transfuse platelets [Volume]
10424-0 http://loinc.org Transfuse erythrocytes [Volume]
10425-7 http://loinc.org Transfuse Rh immune globulin [Volume]
10426-5 http://loinc.org Transfuse whole blood [Volume]
10427-3 http://loinc.org Transfuse whole blood autologous [Volume]
10428-1 http://loinc.org Varicella zoster virus immune globulin given [Volume]
10429-9 http://loinc.org AE 1 Ag [Presence] in Tissue by Immune stain
1043-9 http://loinc.org H Ab [Presence] in Serum or Plasma from donor Donor
10430-7 http://loinc.org AE 3 Ag [Presence] in Tissue by Immune stain
10431-5 http://loinc.org B-cell Ag [Presence] in Tissue by Immune stain
10432-3 http://loinc.org CD30 Ag [Presence] in Tissue by Immune stain
10433-1 http://loinc.org BR-2 Ag [Presence] in Tissue by Immune stain
10434-9 http://loinc.org Complement C3 Ag [Presence] in Tissue by Immune stain
10435-6 http://loinc.org C5B-9 Ag [Presence] in Tissue by Immune stain
10436-4 http://loinc.org CD15 Ag [Presence] in Tissue by Immune stain
10437-2 http://loinc.org CD16 Ag [Presence] in Tissue by Immune stain
10438-0 http://loinc.org CD20 Ag [Presence] in Tissue by Immune stain
10439-8 http://loinc.org CD3 Ag [Presence] in Tissue by Immune stain
1044-7 http://loinc.org H Ab [Presence] in Serum
10440-6 http://loinc.org Deprecated CD30 Ag [Presence] in Tissue by Immune stain
10441-4 http://loinc.org CD34 Ag [Presence] in Tissue by Immune stain
10442-2 http://loinc.org CD56 Ag [Presence] in Tissue by Immune stain
10443-0 http://loinc.org CD43 T-cell monocyte+myeloid cell Ag [Presence] in Tissue by Immune stain
10444-8 http://loinc.org CD57 Ag [Presence] in Tissue by Immune stain
10445-5 http://loinc.org CD11c Ag [Presence] in Tissue by Immune stain
10446-3 http://loinc.org Leukocyte common Ag [Presence] in Tissue by Immune stain
10447-1 http://loinc.org M-5 Ag [Presence] in Tissue by Immune stain
10448-9 http://loinc.org T-cell Ag [Presence] in Tissue by Immune stain
10449-7 http://loinc.org Glucose [Mass/volume] in Serum or Plasma --1 hour post meal
1045-4 http://loinc.org H NOS Ab [Presence] in Serum or Plasma from Blood product unit
10450-5 http://loinc.org Glucose [Mass/volume] in Serum or Plasma --10 hours fasting
10451-3 http://loinc.org Proinsulin [Moles/volume] in Serum or Plasma --12 hours fasting
10452-1 http://loinc.org Xylose [Mass/volume] in Serum or Plasma --1 hour post 25 g xylose PO
10453-9 http://loinc.org Xylose [Mass/volume] in Serum or Plasma --1 hour post dose xylose PO
10454-7 http://loinc.org Xylose [Mass/volume] in Serum or Plasma --2 hours post 25 g xylose PO
10455-4 http://loinc.org Xylose [Mass/volume] in Serum or Plasma --30 minutes post 25 g xylose PO
10456-2 http://loinc.org Xylose [Mass/volume] in Serum or Plasma --6 hours fasting
10457-0 http://loinc.org Actin Ag [Presence] in Tissue by Immune stain
10458-8 http://loinc.org Alkaline phosphatase.placental Ag [Presence] in Tissue by Immune stain
10459-6 http://loinc.org Alpha-1-Fetoprotein Ag [Presence] in Tissue by Immune stain
1046-2 http://loinc.org H NOS Ab [Presence] in Serum or Plasma from donor Donor
10460-4 http://loinc.org Lactalbumin alpha Ag [Presence] in Tissue by Immune stain
10461-2 http://loinc.org Alpha-1-Antichymotrypsin Ag [Presence] in Tissue by Immune stain
10462-0 http://loinc.org Alpha 1 antitrypsin Ag [Presence] in Tissue by Immune stain
10463-8 http://loinc.org Amyloid A component Ag [Presence] in Tissue by Immune stain
10464-6 http://loinc.org Amyloid P component Ag [Presence] in Tissue by Immune stain
10465-3 http://loinc.org Amyloid.prealbumin Ag [Presence] in Tissue by Immune stain
10466-1 http://loinc.org Anion gap 3 in Serum or Plasma
10467-9 http://loinc.org Beta-2-Microglobulin amyloid Ag [Presence] in Tissue by Immune stain
10468-7 http://loinc.org Calcitonin Ag [Presence] in Tissue by Immune stain
10469-5 http://loinc.org Carcinoembryonic Ag [Presence] in Tissue by Immune stain
1047-0 http://loinc.org H NOS Ab [Presence] in Serum or Plasma
10470-3 http://loinc.org Choriogonadotropin Ag [Presence] in Tissue by Immune stain
10471-1 http://loinc.org Chromogranin A Ag [Presence] in Tissue by Immune stain
10472-9 http://loinc.org Chromogranin Ag [Presence] in Tissue by Immune stain
10473-7 http://loinc.org Chymotrypsin Ag [Presence] in Tissue by Immune stain
10474-5 http://loinc.org Collagen type 4 Ag [Presence] in Tissue by Immune stain
10475-2 http://loinc.org Corticotropin Ag [Presence] in Tissue by Immune stain
10476-0 http://loinc.org Desmin Ag [Presence] in Tissue by Immune stain
10477-8 http://loinc.org Enolase.neuron specific Ag [Presence] in Tissue by Immune stain
10478-6 http://loinc.org Eosinophil major basic protein Ag [Presence] in Tissue by Immune stain
10479-4 http://loinc.org CD227 Ag [Presence] in Tissue by Immune stain
1048-8 http://loinc.org H NOS Ag [Presence] on Red Blood Cells from Blood product unit
10480-2 http://loinc.org Estrogen+Progesterone receptor Ag [Presence] in Tissue by Immune stain
10481-0 http://loinc.org Follitropin.alpha subunit Ag [Presence] in Tissue by Immune stain
10482-8 http://loinc.org Follitropin.beta subunit Ag [Presence] in Tissue by Immune stain
10483-6 http://loinc.org Gastrin Ag [Presence] in Tissue by Immune stain
10484-4 http://loinc.org Glial fibrillary acidic protein Ag [Presence] in Tissue by Immune stain
10485-1 http://loinc.org Glucagon Ag [Presence] in Tissue by Immune stain
10486-9 http://loinc.org Hemoglobin Ag [Presence] in Tissue by Immune stain
10487-7 http://loinc.org HMB-45 Ag [Presence] in Tissue by Immune stain
10488-5 http://loinc.org IgA Ag [Presence] in Tissue by Immune stain
10489-3 http://loinc.org IgA.heavy chain Ag [Presence] in Tissue by Immune stain
1049-6 http://loinc.org H NOS Ag [Presence] on Red Blood Cells from donor Donor
10490-1 http://loinc.org IgE Ag [Presence] in Tissue by Immune stain
10491-9 http://loinc.org IgG Ag [Presence] in Tissue by Immune stain
10492-7 http://loinc.org IgG.heavy chain Ag [Presence] in Tissue by Immune stain
10493-5 http://loinc.org IgM Ag [Presence] in Tissue by Immune stain
10494-3 http://loinc.org IgM.heavy chain Ag [Presence] in Tissue by Immune stain
10495-0 http://loinc.org Insulin Ag [Presence] in Tissue by Immune stain
10496-8 http://loinc.org Immunoglobulin Kappa light chains.kappa chains Ag [Presence] in Tissue by Immune stain
10497-6 http://loinc.org Immunoglobulin light chains.kappa amyloid Ag [Presence] in Tissue by Immune stain
10498-4 http://loinc.org Keratin Ag [Presence] in Tissue by Immune stain
10499-2 http://loinc.org Immunoglobulin Lambda light chains.lambda chains Ag [Presence] in Tissue by Immune stain
105-7 http://loinc.org Ceforanide [Susceptibility] by Disk diffusion (KB)
1050-4 http://loinc.org H NOS Ag [Presence] on Red Blood Cells
10500-7 http://loinc.org Immunoglobulin light chains.lambda amyloid Ag [Presence] in Tissue by Immune stain
10501-5 http://loinc.org Lutropin [Units/volume] in Serum or Plasma
10502-3 http://loinc.org Lutropin Ag [Presence] in Tissue by Immune stain
10503-1 http://loinc.org Lysozyme Ag [Presence] in Tissue by Immune stain
10504-9 http://loinc.org Myelin basic protein Ag [Presence] in Tissue by Immune stain
10505-6 http://loinc.org Myoglobin Ag [Presence] in Tissue by Immune stain
10506-4 http://loinc.org Peanut agglutinin Ag [Presence] in Tissue by Immune stain
10507-2 http://loinc.org Prolactin Ag [Presence] in Tissue by Immune stain
10508-0 http://loinc.org Prostate specific Ag [Presence] in Tissue by Immune stain
10509-8 http://loinc.org Prostatic acid phosphatase Ag [Presence] in Tissue by Immune stain
1051-2 http://loinc.org Hemolytic disease of newborn screen [Interpretation] in Blood
10510-6 http://loinc.org S-100 Ag Ag [Presence] in Tissue by Immune stain
10511-4 http://loinc.org Serotonin Ag [Presence] in Tissue by Immune stain
10512-2 http://loinc.org Somatostatin Ag [Presence] in Tissue by Immune stain
10513-0 http://loinc.org Somatotropin Ag [Presence] in Tissue by Immune stain
10514-8 http://loinc.org Synaptophysin Ag [Presence] in Tissue by Immune stain
10515-5 http://loinc.org Thyroglobulin Ag [Presence] in Tissue by Immune stain
10516-3 http://loinc.org Thyrotropin Ag [Presence] in Tissue by Immune stain
10517-1 http://loinc.org Trypsin Ag [Presence] in Tissue by Immune stain
10518-9 http://loinc.org Ulex europaeus I lectin Ag [Presence] in Tissue by Immune stain
10519-7 http://loinc.org Vimentin Ag [Presence] in Tissue by Immune stain
1052-0 http://loinc.org Deprecated I (intermediate) subtype [Presence] in Serum or Plasma from Blood product unit
10520-5 http://loinc.org Coagulation factor VI Ag [Presence] in Tissue by Immune stain
10521-3 http://loinc.org Coagulation factor VIII Ag [Presence] in Tissue by Immune stain
10522-1 http://loinc.org Coagulation factor XIII Ag [Presence] in Tissue by Immune stain
10523-9 http://loinc.org Fibrinogen Ag [Presence] in Tissue by Immune stain
10524-7 http://loinc.org Microscopic observation [Identifier] in Cervix by Cyto stain
10525-4 http://loinc.org Microscopic observation [Identifier] in Unspecified specimen by Cyto stain
10526-2 http://loinc.org Microscopic observation [Identifier] in Sputum by Cyto stain
10527-0 http://loinc.org Microscopic observation [Identifier] in Tissue by Cyto stain
10528-8 http://loinc.org Acetophenazine [Mass/volume] in Serum or Plasma
10529-6 http://loinc.org Amoxapine metabolite [Mass/volume] in Serum or Plasma
1053-8 http://loinc.org Deprecated I (intermediate) subtype [Presence] in serum or plasma from donor
10530-4 http://loinc.org Aprobarbital [Mass/volume] in Serum or Plasma
10531-2 http://loinc.org Bretylium [Mass/volume] in Serum or Plasma
10532-0 http://loinc.org Deprecated Desethylamiodarone [Mass/volume] in Serum or Plasma
10533-8 http://loinc.org Propoxyphene+Acetaminophen [Mass/volume] in Serum or Plasma
10534-6 http://loinc.org Diazoxide [Mass/volume] in Serum or Plasma
10535-3 http://loinc.org Digoxin [Mass/volume] in Serum or Plasma
10536-1 http://loinc.org Dipyridamole [Mass/volume] in Serum or Plasma
10537-9 http://loinc.org Deprecated Doxepin+Nordoxepin [Mass/volume] in Serum or Plasma
10538-7 http://loinc.org Deprecated Fluoxetine+Norfluoxetine [Mass/volume] in Serum or Plasma
10539-5 http://loinc.org Glipizide [Mass/volume] in Serum or Plasma
1054-6 http://loinc.org Deprecated I (intermediate) subtype [Presence] in srum
10540-3 http://loinc.org Glyburide [Mass/volume] in Serum or Plasma
10541-1 http://loinc.org Mepivacaine [Mass/volume] in Serum or Plasma
10542-9 http://loinc.org Metharbital [Mass/volume] in Serum or Plasma
10543-7 http://loinc.org Methsuximide+Normethsuximide [Mass/volume] in Serum or Plasma
10544-5 http://loinc.org Normeperidine [Presence] in Serum or Plasma
10545-2 http://loinc.org Normephenytoin [Mass/volume] in Serum or Plasma
10546-0 http://loinc.org Normethsuximide [Mass/volume] in Serum or Plasma
10547-8 http://loinc.org Primidone+Phenobarbital [Mass/volume] in Serum or Plasma
10548-6 http://loinc.org Phenytoin Free/Phenytoin.total in Serum or Plasma
10549-4 http://loinc.org Pirmenol [Mass/volume] in Serum or Plasma
1055-3 http://loinc.org Deprecated I (intermediate) subtype [Presence] on Red Blood Cells from Blood product unit
10550-2 http://loinc.org Deprecated Temazepam [Mass/volume] in Serum or Plasma
10551-0 http://loinc.org Triamterene [Mass/volume] in Serum or Plasma
10552-8 http://loinc.org Tricyclic antidepressants [Mass/volume] in Serum or Plasma
10553-6 http://loinc.org Prostatic acid phosphatase [Enzymatic activity/volume] in Genital fluid
10554-4 http://loinc.org Deprecated Prostatic acid phosphatase [Enzymatic activity/volume] in Seminal plasma
10555-1 http://loinc.org Acrosin [Entitic Catalytic Activity] in Spermatozoa
10556-9 http://loinc.org Deprecated Adenosine triphosphatase [Enzymatic activity/volume] in Seminal plasma
10557-7 http://loinc.org Adenosine triphosphate [Moles/volume] in Semen
10558-5 http://loinc.org Albumin [Moles/volume] in Semen
10559-3 http://loinc.org Deprecated Calcium [Molecules/volume] in Semen
1056-1 http://loinc.org Deprecated I (intermediate) subtype [Presence] on Red Blood Cells from donor
10560-1 http://loinc.org Carcinoembryonic Ag [Units/volume] in Semen
10561-9 http://loinc.org Carnitine [Moles/volume] in Semen
10562-7 http://loinc.org Cells [#/volume] in Cervical mucus
10563-5 http://loinc.org Cells other than spermatozoa [#/volume] in Semen
10564-3 http://loinc.org Cervical mucus [Volume]
10565-0 http://loinc.org Choriogonadotropin [Units/volume] in Semen
10566-8 http://loinc.org Deprecated Choriogonadotropin [Molecules/volume] in Semen
10567-6 http://loinc.org Citrate [Moles/volume] in Semen
10568-4 http://loinc.org Clarity of Semen
10569-2 http://loinc.org Color of Semen
1057-9 http://loinc.org Deprecated I (intermediate) subtype [Presence] on Red Blood Cells
10570-0 http://loinc.org Consistency of Cervical mucus
10571-8 http://loinc.org Deprecated Consistency of Semen
10572-6 http://loinc.org Deprecated Duration^post ejaculation
10573-4 http://loinc.org Ferning [Type] in Cervical mucus
10574-2 http://loinc.org Fructose [Moles/volume] in Semen
10575-9 http://loinc.org Deprecated Gamma glutamyl transferase [Enzymatic activity/volume] in Semen
10576-7 http://loinc.org Germ cells.immature [#/volume] in Semen
10577-5 http://loinc.org Glucosidase [Enzymatic activity/volume] in Seminal plasma
10578-3 http://loinc.org Glycerophosphocholine [Moles/volume] in Seminal plasma
10579-1 http://loinc.org Leukocytes [#/volume] in Semen
1058-7 http://loinc.org I Ab [Presence] in Serum or Plasma from Blood product unit
10580-9 http://loinc.org Liquefaction [Time] in Semen
10581-7 http://loinc.org Deprecated Number of entities [#] in Spermatozoa
10582-5 http://loinc.org pH of Cervical mucus
10583-3 http://loinc.org Prostaglandin F1 alpha [Moles/volume] in Semen
10584-1 http://loinc.org Deprecated Protein [Mass/volume] in Semen
10585-8 http://loinc.org Round cells [#/volume] in Semen
10586-6 http://loinc.org Deprecated Volume of Semen
10587-4 http://loinc.org Sexual abstinence duration
10588-2 http://loinc.org Spermatogonia [#/volume] in Semen
10589-0 http://loinc.org Spermatids [#/volume] in Semen by Streptoavidin-biotin method (SAB)
1059-5 http://loinc.org I Ab [Presence] in Serum or Plasma from donor Donor
10590-8 http://loinc.org Spermatids [#/volume] in Semen by Sertoli cell barrier method (SCB)
10591-6 http://loinc.org Primary Spermatocytes [#/volume] in Semen
10592-4 http://loinc.org Secondary Spermatocytes [#/volume] in Semen
10593-2 http://loinc.org Spermatozoa Pyriform Head/100 spermatozoa in Semen
10594-0 http://loinc.org Spermatozoa Tapering Head/100 spermatozoa in Semen
10595-7 http://loinc.org Deprecated Spermatozoa [#/volume] in Semen
10596-5 http://loinc.org Deprecated Spermatozoa Ab in cervical mucosa
10597-3 http://loinc.org Deprecated Spermatozoa Ab in semen
10598-1 http://loinc.org Deprecated Spermatozoa Ab in serum
10599-9 http://loinc.org Spermatozoa penetration [Presence] in Seminal fluid and Cervical mucosa by Kremer test
106-5 http://loinc.org Ceforanide [Susceptibility] by Serum bactericidal titer
1060-3 http://loinc.org I Ab [Presence] in Serum or Plasma
10600-5 http://loinc.org Spermatozoa penetration [Presence] in Seminal fluid and Cervical mucosa
10601-3 http://loinc.org Spermatozoa penetration [Presence] in Seminal fluid and Cervical mucosa --post coitus
10602-1 http://loinc.org Spermatozoa Abnormal Head/100 spermatozoa in Semen
10603-9 http://loinc.org Spermatozoa Abnormal Midpiece/100 spermatozoa in Semen
10604-7 http://loinc.org Spermatozoa Abnormal Tail/100 spermatozoa in Semen
10605-4 http://loinc.org Spermatozoa Agglutinated/100 spermatozoa in Semen
10606-2 http://loinc.org Spermatozoa Amorphous Head/100 spermatozoa in Semen
10607-0 http://loinc.org Spermatozoa Coiled Tail/100 spermatozoa in Semen
10608-8 http://loinc.org Spermatozoa Cytoplasmic Droplet/100 spermatozoa in Semen
10609-6 http://loinc.org Spermatozoa Duplicate Head/100 spermatozoa in Semen
1061-1 http://loinc.org I NOS Ab [Presence] in Serum or Plasma from Blood product unit
10610-4 http://loinc.org Spermatozoa Duplicate Tail/100 spermatozoa in Semen
10611-2 http://loinc.org Spermatozoa Immotile/100 spermatozoa in Semen
10612-0 http://loinc.org Spermatozoa Large Oval Head/100 spermatozoa in Semen
10613-8 http://loinc.org Spermatozoa Viable/100 spermatozoa in Semen
10614-6 http://loinc.org Spermatozoa Motile w IgA/100 spermatozoa in Semen by Immunobead
10615-3 http://loinc.org Spermatozoa Motile w IgA/100 spermatozoa in Semen by Mixed antiglobulin reaction
10616-1 http://loinc.org Spermatozoa Motile w IgG/100 spermatozoa in Semen by Immunobead
10617-9 http://loinc.org Spermatozoa Motile w IgG/100 spermatozoa in Semen by Mixed antiglobulin reaction
10618-7 http://loinc.org Spermatozoa Motile w IgM/100 spermatozoa in Semen by Immunobead
10619-5 http://loinc.org Spermatozoa Motile w IgM/100 spermatozoa in Semen by Mixed antiglobulin reaction
1062-9 http://loinc.org I NOS Ab [Presence] in Serum or Plasma from donor Donor
10620-3 http://loinc.org Spermatozoa Nonprogressive/100 spermatozoa in Semen
10621-1 http://loinc.org Spermatozoa Normal Head/100 spermatozoa in Semen
10622-9 http://loinc.org Spermatozoa Normal/100 spermatozoa in Semen
10623-7 http://loinc.org Spermatozoa Pin Head/100 spermatozoa in Semen
10624-5 http://loinc.org Spermatozoa Rapid/100 spermatozoa in Semen
10625-2 http://loinc.org Spermatozoa Round Head/100 spermatozoa in Semen
10626-0 http://loinc.org Spermatozoa Slow/100 spermatozoa in Semen
10627-8 http://loinc.org Spermatozoa Small Oval Head/100 spermatozoa in Semen
10628-6 http://loinc.org Spermatozoa Tail Swelling/100 spermatozoa in Semen
10629-4 http://loinc.org Spermatozoa Vacuolated Head/100 spermatozoa in Semen
1063-7 http://loinc.org I NOS Ab [Presence] in Serum or Plasma
10630-2 http://loinc.org Spinnbarkeit [Length] in Cervical mucus
10631-0 http://loinc.org Testosterone [Moles/volume] in Semen
10632-8 http://loinc.org Time until next menstrual period
10633-6 http://loinc.org Zinc [Moles/volume] in Semen
10634-4 http://loinc.org Complement C1 esterase inhibitor.functional/Complement C1 esterase inhibitor.total in Serum or Plasma
10635-1 http://loinc.org Acanthamoeba sp identified in Eye by Organism specific culture
10636-9 http://loinc.org Acanthamoeba sp identified in Eye by Wet preparation
10637-7 http://loinc.org Microscopic observation [Identifier] in Tissue by Night blue stain
10638-5 http://loinc.org Thermophilic Actinomycetes colony count [#/volume] in Unspecified specimen by Organism specific culture
10639-3 http://loinc.org Thermophilic Actinomycetes identified in Unspecified specimen by Organism specific culture
1064-5 http://loinc.org I NOS Ag [Presence] on Red Blood Cells from Blood product unit
10640-1 http://loinc.org Deprecated Adenovirus 40+41 [Identifier] in Stool by Electron microscopy
10641-9 http://loinc.org Amoeba identified in Aspirate by Immune stain
10642-7 http://loinc.org Amoeba identified in Aspirate by Wet preparation
10643-5 http://loinc.org Amoeba identified in Stool by Organism specific culture
10644-3 http://loinc.org Arthropod identified in Unspecified specimen
10645-0 http://loinc.org Aspergillus fumigatus Ag [Presence] in Tissue by Immunofluorescence
10646-8 http://loinc.org Astrovirus [Identifier] in Stool by Electron microscopy
10647-6 http://loinc.org Babesia sp identified in Blood by Thick film
10648-4 http://loinc.org Babesia sp identified in Blood by Thin film
10649-2 http://loinc.org Calicivirus [Identifier] in Stool by Electron microscopy
1065-2 http://loinc.org I NOS Ag [Presence] on Red Blood Cells from donor Donor
10650-0 http://loinc.org Candida sp DNA [Presence] in Blood by Probe with amplification
10651-8 http://loinc.org Chlamydophila pneumoniae Ag [Presence] in Sputum or Bronchial
10652-6 http://loinc.org Chlamydophila pneumoniae DNA [Presence] in Sputum or Bronchial by Probe with amplification
10653-4 http://loinc.org Clotrimazole [Susceptibility] by Minimum inhibitory concentration (MIC)
10654-2 http://loinc.org Clotrimazole [Susceptibility] by Minimum lethal concentration (MLC)
10655-9 http://loinc.org Coccidia identified in Duodenal fluid by Acid fast stain
10656-7 http://loinc.org Coccidia identified in Stool by Acid fast stain
10657-5 http://loinc.org Deprecated Cryptococcus neoformans Ag [Presence] in Tissue by Immunofluorescence
10658-3 http://loinc.org Cyanobacterium identified in Water by Light microscopy
10659-1 http://loinc.org Cyclospora sp identified in Stool by Acid fast stain
1066-0 http://loinc.org I NOS Ag [Presence] on Red Blood Cells
10660-9 http://loinc.org Cytomegalovirus Ag [Presence] in Tissue by Immune stain
10661-7 http://loinc.org Dinoflagellate identified in Water by Light microscopy
10662-5 http://loinc.org Filaria identified in Blood by Concentration
10663-3 http://loinc.org Filaria identified in Blood by Thick film
10664-1 http://loinc.org Filaria identified in Blood by Thin film
10665-8 http://loinc.org Fungus colony count [#/volume] in Unspecified specimen by Environmental culture
10666-6 http://loinc.org Fungus identified in Tissue by Fontana-Masson stain
10667-4 http://loinc.org Fungus identified in Unspecified specimen by Animal inoculation
10668-2 http://loinc.org Fungus identified in Unspecified specimen by Environmental culture
10669-0 http://loinc.org Fungus identified in Unspecified specimen by Sticky tape for environmental fungus
1067-8 http://loinc.org Jk sup(a) Ab [Presence] in Serum or Plasma from Blood product unit
10670-8 http://loinc.org Giardia lamblia [Presence] in Stool by Organism specific culture
10671-6 http://loinc.org Helminth identified in Unspecified specimen
10672-4 http://loinc.org Helminth+Arthropod identified in Unspecified specimen
10673-2 http://loinc.org Hepatitis B virus core Ag [Presence] in Tissue by Immune stain
10674-0 http://loinc.org Hepatitis B virus surface Ag [Presence] in Tissue by Immune stain
10675-7 http://loinc.org Hepatitis B virus surface Ag [Presence] in Tissue by Orcein stain
10676-5 http://loinc.org Hepatitis C virus RNA [Units/volume] (viral load) in Serum or Plasma by Probe with amplification
10677-3 http://loinc.org Herpes simplex virus 1 Ag [Presence] in Tissue by Immune stain
10678-1 http://loinc.org Herpes simplex virus 1+2 Ag [Presence] in Tissue by Immune stain
10679-9 http://loinc.org Herpes simplex virus 2 Ag [Presence] in Tissue by Immune stain
1068-6 http://loinc.org Jk sup(a) Ab [Presence] in Serum or Plasma from Donor
10680-7 http://loinc.org Herpes simplex virus identified in Cerebral spinal fluid by Electron microscopy
10681-5 http://loinc.org Herpes simplex virus identified in Tissue by Electron microscopy
10682-3 http://loinc.org Deprecated HIV 1 RNA [Units/volume] in Serum or Plasma by Probe with amplification
10683-1 http://loinc.org Hydatid cyst identified in Aspirate by Immune stain
10684-9 http://loinc.org Hydatid cyst identified in Liver by Wet preparation
10685-6 http://loinc.org Hydatid cyst identified in Lung tissue by Wet preparation
10686-4 http://loinc.org Leishmania sp identified in Tissue by Giemsa stain
10687-2 http://loinc.org Leishmania sp identified in Tissue by Organism specific culture
10688-0 http://loinc.org Microscopic observation [Identifier] in Hair by KOH preparation
10689-8 http://loinc.org Microscopic observation [Identifier] in Nail by KOH preparation
1069-4 http://loinc.org Jk sup(a) Ab [Presence] in Serum or Plasma
10690-6 http://loinc.org Microsporidia identified in Duodenal fluid by Trichrome stain modified
10691-4 http://loinc.org Mushroom.toxic identified by Inspection
10692-2 http://loinc.org Mushroom.toxic identified in Food by Light microscopy
10693-0 http://loinc.org Mushroom.toxic identified in Vomitus by Light microscopy
10694-8 http://loinc.org Naegleria sp identified in Tissue by Organism specific culture
10695-5 http://loinc.org Naegleria sp identified in Tissue by Wet preparation
10696-3 http://loinc.org Norovirus [Identifier] in Stool by Electron microscopy
10697-1 http://loinc.org Nystatin [Susceptibility] by Minimum inhibitory concentration (MIC)
10698-9 http://loinc.org Nystatin [Susceptibility] by Minimum lethal concentration (MLC)
10699-7 http://loinc.org Onchocerca sp identified in Tissue by Wet preparation
107-3 http://loinc.org Cefotaxime [Susceptibility] by Minimum lethal concentration (MLC)
1070-2 http://loinc.org Jk sup(a) Ag [Presence] on Red Blood Cells from Blood product unit
10700-3 http://loinc.org Orthopoxvirus [Identifier] in Skin by Electron microscopy
10701-1 http://loinc.org Ova and parasites identified in Stool by Concentration
10702-9 http://loinc.org Ova and parasites identified in Stool by Immune stain
10703-7 http://loinc.org Ova and parasites identified in Stool by Kinyoun iron hematoxylin stain
10704-5 http://loinc.org Ova and parasites identified in Stool by Light microscopy
10705-2 http://loinc.org Human papilloma virus Ag [Presence] in Tissue by Immune stain
10706-0 http://loinc.org Picornavirus [Identifier] in Stool by Electron microscopy
10707-8 http://loinc.org Toxic Plant identified in Plant specimen by Inspection
10708-6 http://loinc.org Toxic Plant identified in Vomitus by Light microscopy
10709-4 http://loinc.org Plasmodium falciparum Ag [Units/volume] in Blood by Immunofluorescence
1071-0 http://loinc.org Jk sup(a) Ag [Presence] on Red Blood Cells from Donor
10710-2 http://loinc.org Plasmodium sp identified in Blood by Thin film
10711-0 http://loinc.org Plasmodium vivax Ag [Units/volume] in Blood by Immunofluorescence
10712-8 http://loinc.org Pneumocystis sp identified in Lung tissue
10713-6 http://loinc.org Prototheca identified in Unspecified specimen by Culture
10714-4 http://loinc.org Deprecated Rotavirus [Identifier] in Stool by Electron microscopy
10715-1 http://loinc.org Schistosoma sp identified in Urine sediment by Light microscopy
10716-9 http://loinc.org Schistosoma sp identified in Unspecified specimen by Organism specific culture
10717-7 http://loinc.org Streptococcus pneumoniae Ab [Units/volume] in Serum by Latex agglutination
10718-5 http://loinc.org Strongyloides sp Ab [Units/volume] in Serum by Immunoassay
10719-3 http://loinc.org Taenia solium adult Ab [Units/volume] in Serum by Immunoblot
1072-8 http://loinc.org Jk sup(a) Ag [Presence] on Red Blood Cells
10720-1 http://loinc.org Terbinafine [Susceptibility] by Minimum inhibitory concentration (MIC)
10721-9 http://loinc.org Terbinafine [Susceptibility] by Minimum lethal concentration (MLC)
10722-7 http://loinc.org Torovirus [Identifier] in Stool by Electron microscopy
10723-5 http://loinc.org Toxoplasma gondii IgA Ab [Units/volume] in Serum by Immunoassay
10724-3 http://loinc.org Toxoplasma gondii IgE Ab [Units/volume] in Serum by Immunoassay
10725-0 http://loinc.org Toxoplasma gondii DNA [Units/volume] in Body fluid by Probe with amplification
10726-8 http://loinc.org Toxoplasma gondii [Presence] in Tissue by Giemsa stain
10727-6 http://loinc.org Toxoplasma gondii identified in Tissue
10728-4 http://loinc.org Trichomonas sp identified in Genital specimen by Organism specific culture
10729-2 http://loinc.org Trypanosoma sp identified in Blood by Light microscopy
1073-6 http://loinc.org Jk sup(b) Ab [Presence] in Serum or Plasma from Blood product unit
10730-0 http://loinc.org Trypanosoma sp identified in Blood by Organism specific culture
10731-8 http://loinc.org Trypanosoma sp identified in Blood by Thick film
10732-6 http://loinc.org Trypanosoma sp identified in Blood by Thin film
10733-4 http://loinc.org Trypanosoma sp identified in Blood by Wet preparation
10734-2 http://loinc.org Varicella zoster virus identified in Skin by Electron microscopy
10735-9 http://loinc.org Viral sequencing [Identifier] in Serum by Sequencing
10736-7 http://loinc.org Virus identified in Cerebral spinal fluid by Electron microscopy
10737-5 http://loinc.org Virus identified in Stool by Electron microscopy
10738-3 http://loinc.org Virus identified in Tissue by Electron microscopy
10739-1 http://loinc.org Virus identified in Unspecified specimen by Electron microscopy
1074-4 http://loinc.org Jk sup(b) Ab [Presence] in Serum or Plasma from Donor
10740-9 http://loinc.org Aluminum.microscopic observation [Identifier] in Bone by Histomorphometry stain
10741-7 http://loinc.org Amyloid.microscopic observation [Identifier] in Brain by Thioflavine-S stain
10742-5 http://loinc.org Amyloid.microscopic observation [Identifier] in Tissue by Bennhold stain.Putchler modified
10743-3 http://loinc.org Amyloid.microscopic observation [Identifier] in Tissue by Highman stain
10744-1 http://loinc.org Amyloid.microscopic observation [Identifier] in Tissue by Vassar-culling stain
10745-8 http://loinc.org Bile.microscopic observation [Identifier] in Tissue by Fouchet stain
10746-6 http://loinc.org Calcium.microscopic observation [Identifier] in Tissue by Von Kossa stain
10747-4 http://loinc.org Collagen fibers+Elastic fibers.microscopic observation [Identifier] in Tissue by Lawson-Van Gieson stain
10748-2 http://loinc.org Collagen fibers+Elastic fibers.microscopic observation [Identifier] in Tissue by Verhoeff-Van Gieson stain
10749-0 http://loinc.org Collagen fibers.microscopic observation [Identifier] in Tissue by Van Gieson stain
1075-1 http://loinc.org Jk sup(b) Ab [Presence] in Serum or Plasma
10750-8 http://loinc.org Connective tissue.microscopic observation [Identifier] in Tissue by Trichrome stain.Masson
10751-6 http://loinc.org Copper.microscopic observation [Identifier] in Tissue by Rhodamine stain
10752-4 http://loinc.org Fat.microscopic observation [Identifier] in Milk by Sudan IV stain
10753-2 http://loinc.org Fat.microscopic observation [Identifier] in Stool by Sudan IV stain
10754-0 http://loinc.org Fat.microscopic observation [Identifier] in Tissue by Sudan IV stain
10755-7 http://loinc.org Fungus.microscopic observation [Identifier] in Tissue by Methenamine silver stain.Grocott
10756-5 http://loinc.org Glial fibers.microscopic observation [Identifier] in Tissue by Holzer stain
10757-3 http://loinc.org Hematologic+Nuclear elements.microscopic observation [Identifier] in Tissue by Giemsa stain.May-Grunwald
10758-1 http://loinc.org Iron.microscopic observation [Identifier] in Bone by Histomorphometry stain
10759-9 http://loinc.org Iron.microscopic observation [Identifier] in Sputum by Gomori stain
1076-9 http://loinc.org Jk sup(b) Ag [Presence] on Red Blood Cells from Blood product unit
10760-7 http://loinc.org Iron.microscopic observation [Identifier] in Tissue by Gomori stain
10761-5 http://loinc.org Iron.microscopic observation [Identifier] in Tissue by Other stain
10762-3 http://loinc.org Microscopic observation [Identifier] in Blood by Hemosiderin stain
10763-1 http://loinc.org Microscopic observation [Identifier] in Body fluid by Sudan black stain
10764-9 http://loinc.org Microscopic observation [Identifier] in Sputum by Silver stain
10765-6 http://loinc.org Microscopic observation [Identifier] in Tissue by Acetate esterase stain
10766-4 http://loinc.org Microscopic observation [Identifier] in Tissue by Alcian blue stain
10767-2 http://loinc.org Microscopic observation [Identifier] in Tissue by Alcian blue stain.sulfated
10768-0 http://loinc.org Microscopic observation [Identifier] in Tissue by Alcian blue stain.with periodic acid-Schiff
10769-8 http://loinc.org Microscopic observation [Identifier] in Tissue by Alizarin red S stain
1077-7 http://loinc.org Jk sup(b) Ag [Presence] on Red Blood Cells from Donor
10770-6 http://loinc.org Microscopic observation [Identifier] in Tissue by Argentaffin stain
10771-4 http://loinc.org Deprecated Microscopic observation [Identifier] in Tissue by Rhodamine-auramine fluorochrome stain
10772-2 http://loinc.org Microscopic observation [Identifier] in Tissue by Azure-eosin stain
10773-0 http://loinc.org Microscopic observation [Identifier] in Tissue by Basic fuchsin stain
10774-8 http://loinc.org Microscopic observation [Identifier] in Tissue by Bielschowsky stain
10775-5 http://loinc.org Microscopic observation [Identifier] in Tissue by Bleach stain
10776-3 http://loinc.org Microscopic observation [Identifier] in Tissue by Bodian stain
10777-1 http://loinc.org Microscopic observation [Identifier] in Tissue by Brown and Brenn stain
10778-9 http://loinc.org Microscopic observation [Identifier] in Tissue by Butyrate esterase stain
10779-7 http://loinc.org Microscopic observation [Identifier] in Tissue by Carmine stain.Best
1078-5 http://loinc.org Jk sup(b) Ag [Presence] on Red Blood Cells
10780-5 http://loinc.org Microscopic observation [Identifier] in Tissue by Chloracetate esterase stain
10781-3 http://loinc.org Microscopic observation [Identifier] in Tissue by Churukian-Schenk stain
10782-1 http://loinc.org Microscopic observation [Identifier] in Tissue by Congo red stain
10783-9 http://loinc.org Microscopic observation [Identifier] in Tissue by Crystal violet stain
10784-7 http://loinc.org Microscopic observation [Identifier] in Tissue by Esterase stain.non-specific
10785-4 http://loinc.org Microscopic observation [Identifier] in Tissue by Fite-Faraco stain
10786-2 http://loinc.org Deprecated Microscopic observation [Identifier] in Tissue by Giemsa stain.3 micron
10787-0 http://loinc.org Microscopic observation [Identifier] in Tissue by Gridley stain
10788-8 http://loinc.org Microscopic observation [Identifier] in Tissue by Hansel stain
10789-6 http://loinc.org Microscopic observation [Identifier] in Tissue by Hematoxylin-eosin-Harris regressive stain
1079-3 http://loinc.org Js sup(a) Ab [Presence] in Serum or Plasma from Blood product unit
10790-4 http://loinc.org Microscopic observation [Identifier] in Tissue by Hematoxylin-eosin-Mayers progressive stain
10791-2 http://loinc.org Microscopic observation [Identifier] in Tissue by Mallory-Heidenhain stain
10792-0 http://loinc.org Microscopic observation [Identifier] in Tissue by Methenamine silver stain.Jones
10793-8 http://loinc.org Microscopic observation [Identifier] in Tissue by Methyl green stain
10794-6 http://loinc.org Microscopic observation [Identifier] in Tissue by Methyl green-pyronine Y stain
10795-3 http://loinc.org Microscopic observation [Identifier] in Tissue by Methyl violet stain
10796-1 http://loinc.org Microscopic observation [Identifier] in Tissue by Mucicarmine stain
10797-9 http://loinc.org Microscopic observation [Identifier] in Tissue by Neutral red stain
10798-7 http://loinc.org Microscopic observation [Identifier] in Tissue by Oil red O stain
10799-5 http://loinc.org Microscopic observation [Identifier] in Tissue by Pentachrome stain.Movat
108-1 http://loinc.org Cefotaxime [Susceptibility] by Minimum inhibitory concentration (MIC)
1080-1 http://loinc.org Js sup(a) Ab [Presence] in Serum or Plasma from Donor
10800-1 http://loinc.org Microscopic observation [Identifier] in Tissue by Periodic acid-Schiff stain with diatase digestion
10801-9 http://loinc.org Microscopic observation [Identifier] in Tissue by Phosphotungstic acid Hematoxylin (PTAH) Stain
10802-7 http://loinc.org Microscopic observation [Identifier] in Tissue by Prussian blue stain
10803-5 http://loinc.org Microscopic observation [Identifier] in Tissue by Quinacrine fluorescent stain
10804-3 http://loinc.org Microscopic observation [Identifier] in Tissue by Reticulin stain
10805-0 http://loinc.org Microscopic observation [Identifier] in Tissue by Safranin stain
10806-8 http://loinc.org Microscopic observation [Identifier] in Tissue by Schmorl stain
10807-6 http://loinc.org Microscopic observation [Identifier] in Tissue by Sevier-Munger stain
10808-4 http://loinc.org Microscopic observation [Identifier] in Tissue by Silver impregnation stain.Dieterle
10809-2 http://loinc.org Microscopic observation [Identifier] in Tissue by Silver nitrate stain
1081-9 http://loinc.org Js sup(a) Ab [Presence] in Serum or Plasma
10810-0 http://loinc.org Microscopic observation [Identifier] in Tissue by Silver stain.Fontana-Masson
10811-8 http://loinc.org Microscopic observation [Identifier] in Tissue by Silver stain.Grimelius
10812-6 http://loinc.org Microscopic observation [Identifier] in Tissue by Steiner stain
10813-4 http://loinc.org Microscopic observation [Identifier] in Tissue by Sudan black stain
10814-2 http://loinc.org Microscopic observation [Identifier] in Tissue by Supravital stain
10815-9 http://loinc.org Microscopic observation [Identifier] in Tissue by Tetrachrome stain
10816-7 http://loinc.org Deprecated Microscopic observation [Identifier] in Tissue by Toluidine blue O stain
10817-5 http://loinc.org Microscopic observation [Identifier] in Tissue by Trichrome stain.Gomori-Wheatley
10818-3 http://loinc.org Microscopic observation [Identifier] in Tissue by Trichrome stain.Masson modified
10819-1 http://loinc.org Microscopic observation [Identifier] in Tissue by Wade stain
1082-7 http://loinc.org Js sup(a) Ag [Presence] on Red Blood Cells from Blood product unit
10820-9 http://loinc.org Deprecated Microscopic observation [Identifier] in Tissue by Warthin-Starry stain
10821-7 http://loinc.org Deprecated Microscopic observation [Identifier] in Tissue by Wright Giemsa stain
10822-5 http://loinc.org Mucin.microscopic observation [Identifier] in Tissue by Mucicarmine stain.Mayer
10823-3 http://loinc.org Mucopolysaccharides.microscopic observation [Identifier] in Tissue by Colloidal ferric oxide stain.Hale
10824-1 http://loinc.org Myelin+Myelin breakdown products.microscopic observation [Identifier] in Tissue by Luxol fast blue/Periodic acid-Schiff stain
10825-8 http://loinc.org Myelin+Nerve cells.microscopic observation [Identifier] in Tissue by Luxol fast blue/Cresyl violet stain
10826-6 http://loinc.org Nissel.microscopic observation [Identifier] in Tissue by Cresyl echt violet stain
10827-4 http://loinc.org Reticulum.microscopic observation [Identifier] in Tissue by Gomori stain
10828-2 http://loinc.org Urate crystals.microscopic observation [type] in Tissue by De Galantha stain
10829-0 http://loinc.org Silicon [Mass/volume] in Serum or Plasma
1083-5 http://loinc.org Js sup(a) Ag [Presence] on Red Blood Cells from Donor
10830-8 http://loinc.org Deprecated Surgical operation note complications
10831-6 http://loinc.org Surgical operation note complications [Interpretation]
10832-4 http://loinc.org Glucose [Mass/volume] in Serum or Plasma --15 minutes post 50 g lactose PO
10833-2 http://loinc.org Insulin [Mass/volume] in Serum or Plasma --7 hours post 75 g glucose PO
10834-0 http://loinc.org Globulin [Mass/volume] in Serum by calculation
10835-7 http://loinc.org Lipoprotein a [Mass/volume] in Serum or Plasma
10836-5 http://loinc.org Niacin [Mass/volume] in Blood
10837-3 http://loinc.org Organic acids [Presence] in Serum or Plasma
10838-1 http://loinc.org Phosphoserine [Mass/volume] in Serum or Plasma
10839-9 http://loinc.org Troponin I.cardiac [Mass/volume] in Serum or Plasma
1084-3 http://loinc.org Js sup(a) Ag [Presence] on Red Blood Cells
10840-7 http://loinc.org Atropine [Mass/volume] in Urine
10841-5 http://loinc.org Methazolamide [Mass/volume] in Serum or Plasma
10842-3 http://loinc.org Deprecated HLA-DQ1 [Presence]
10843-1 http://loinc.org Deprecated HLA-DQ2 [Presence]
10844-9 http://loinc.org Deprecated HLA-DQ3 [Presence]
10845-6 http://loinc.org Deprecated HLA-DQ4 [Presence]
10846-4 http://loinc.org Borrelia burgdorferi DNA [Presence] in Blood by Probe with amplification
10847-2 http://loinc.org Borrelia burgdorferi DNA [Presence] in Body fluid by Probe with amplification
10848-0 http://loinc.org Chlamydia sp IgG Ab [Titer] in Serum by Immunofluorescence
10849-8 http://loinc.org Chlamydia sp IgM Ab [Titer] in Serum by Immunofluorescence
1085-0 http://loinc.org Js sup(b) Ab [Presence] in Serum or Plasma from Blood product unit
10850-6 http://loinc.org Cyclospora cayetanensis [Presence] in Unspecified specimen
10851-4 http://loinc.org Escherichia coli O157:H7 [Presence] in Stool by Organism specific culture
10852-2 http://loinc.org Deprecated Fungus identified in Blood by Culture
10853-0 http://loinc.org Isospora belli [Presence] in Unspecified specimen by Acid fast stain.Kinyoun modified
10854-8 http://loinc.org Deprecated Midrofilaria identified in Blood by Concentration
10855-5 http://loinc.org Ova and parasites identified in Duodenal fluid or Gastric fluid by Light microscopy
10856-3 http://loinc.org Microscopic observation [Identifier] in Genital mucus by Gram stain
10857-1 http://loinc.org Microsporidia identified in Unspecified specimen by Light microscopy
10858-9 http://loinc.org Teichoate Ab [Presence] in Serum
10859-7 http://loinc.org Trypanosoma sp [Identifier] in Blood by Acridine Orange + Giemsa Stain
1086-8 http://loinc.org Js sup(b) Ab [Presence] in Serum or Plasma from Donor
10860-5 http://loinc.org Varicella zoster virus [Presence] in Unspecified specimen by Organism specific culture
10861-3 http://loinc.org Progesterone receptor [Mass/mass] in Tissue
10862-1 http://loinc.org Basement membrane Ab [Titer] in Serum
10863-9 http://loinc.org Endomysium IgA Ab [Titer] in Serum
10864-7 http://loinc.org Immune complex [Units/volume] in Serum or Plasma by Raji cell assay
10865-4 http://loinc.org Intercellular substance Ab [Presence] in Serum
10866-2 http://loinc.org Sulfatide IgG Ab [Titer] in Serum
10867-0 http://loinc.org Sulfatide IgM Ab [Titer] in Serum
10868-8 http://loinc.org Bacitracin [Susceptibility] by Disk diffusion (KB)
10869-6 http://loinc.org Xylose [Mass/volume] in Blood --3 hours post 25 g xylose PO
1087-6 http://loinc.org Js sup(b) Ab [Presence] in Serum or Plasma
10870-4 http://loinc.org Xylose [Mass/volume] in Blood --4 hours post 25 g xylose PO
10871-2 http://loinc.org Xylose [Mass/volume] in Blood --5 hours post 25 g xylose PO
10872-0 http://loinc.org Xylose [Mass/volume] in Blood --baseline
10873-8 http://loinc.org Beta-2-Microglobulin [Mass/time] in 24 hour Urine
10874-6 http://loinc.org Bombesin [Mass/volume] in Plasma
10875-3 http://loinc.org Carnitine esters [Mass/volume] in Urine
10876-1 http://loinc.org Carnitine esters [Mass/volume] in Serum or Plasma
10877-9 http://loinc.org Carnitine free (C0) [Mass/volume] in Urine
10878-7 http://loinc.org Iodine.protein bound [Mass/volume] in Serum or Plasma
10879-5 http://loinc.org Isovalerylglycine [Mass/volume] in Urine
1088-4 http://loinc.org Js sup(b) Ag [Presence] on Red Blood Cells from Blood product unit
10880-3 http://loinc.org Magnesium [Mass/mass] in Stool
10881-1 http://loinc.org Pentacarboxylporphyrins [Mass/volume] in Red Blood Cells
10882-9 http://loinc.org Pentacarboxylporphyrins [Mass/volume] in Serum or Plasma
10883-7 http://loinc.org Phenolphthalein [Mass/mass] in Stool
10884-5 http://loinc.org Phosphate [Mass/mass] in Stool
10885-2 http://loinc.org Porphyrins [Mass/time] in 24 hour Urine
10886-0 http://loinc.org Prostate Specific Ag Free [Mass/volume] in Serum or Plasma
10887-8 http://loinc.org Pyridinoline [Mass/time] in 24 hour Urine
10888-6 http://loinc.org Lipase [Enzymatic activity/volume] in Urine
10889-4 http://loinc.org Bisacodyl [Mass/mass] in Stool
1089-2 http://loinc.org Js sup(b) Ag [Presence] on Red Blood Cells from Donor
10890-2 http://loinc.org Deprecated Normethsuximide [Mass/volume] in Serum or Plasma
10891-0 http://loinc.org Oxyphenisatin [Mass/mass] in Stool
10892-8 http://loinc.org Pentoxifylline [Mass/volume] in Serum or Plasma
10893-6 http://loinc.org Trenbolone [Mass/volume] in Urine
10894-4 http://loinc.org Aspergillus niger Ab [Presence] in Serum by Immune diffusion (ID)
10895-1 http://loinc.org Clostridium difficile toxin B [Presence] in Stool
10896-9 http://loinc.org Eastern equine encephalitis virus IgG Ab [Titer] in Serum by Immunofluorescence
10897-7 http://loinc.org Eastern equine encephalitis virus IgG Ab [Titer] in Cerebral spinal fluid by Immunofluorescence
10898-5 http://loinc.org Eastern equine encephalitis virus IgM Ab [Titer] in Serum by Immunofluorescence